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ABSTRACT 
 
 
Rodent models play an essential role in the development of new 
chemotherapeutics and dosing regimes.  It is often difficult to carryout a clinical study for 
pediatric cancers due to the small patient population.  Retinoblastoma, a pediatric cancer 
of the eye, is one example of a pediatric cancer that can benefit from preclinical studies.  
Over the years various retinoblastoma rodent models have been developed used to test 
various combination of broad-spectrum systemic chemotherapy.  It was found form these 
studies that the combination of topotecan and carboplatin was effective.  However both 
drugs cause myelosuppression and therefore administrating both of these drugs 
systemically is not possible.  An alternative effective therapy in the clinic was the use of 
a subconjunctival administration.  We thought if we could administer both drugs, one by 
systemic and one by a subconjunctival injection, perhaps we could decrease the 
systemic exposure with good tumor response.  Detailed pharmacokinetic studies were 
conducted to understand the subconjunctival injections of topotecan and carboplatin.  It 
was found that both drugs could successfully penetrate the eye and increase drug 
exposure.  In addition, in the presence of a tumor, drug exposure to the vitreous was 
greater. 
 
Additionally comparative pharmacodynamic studies combining topotecan 
subconjunctival injection with carboplatin intraperitoneal or carboplatin subconjunctival 
injection with topotecan intraperitoneal were conducted.  The tumor response, systemic 
toxicity and local toxicity were studied.  There was tumor response in both combinations 
and no ocular toxicity was seen with a single eye subconjunctival injection for either 
drug.  However, rats that received the combination with topotecan subconjunctival 
injection and carboplatin intraperitoneal experienced great toxicity and morbidity.  The 
data and observations suggest the death is due to dehydration.  Therefore it was 
concluded that the alternative combination was better. 
 
The above data suggested an appropriate drug combination and schedule for a 
preclinical study.  However, the noninvasive methods to follow tumor progression and 
choosing the correct genetic model needed to be determined.  This was essential to 
ensure the preclinical study could be easily translated for future clinical studies.   A 
characterization study of five modalities, retina camera, optomotry, tonometer, 
ultrasound and MRI, was done with retinoblastoma mice.  We determined the feasibility 
of each technique.  It was found that the retina camera could detect the tumor the 
earliest in a high throughput manner.  Additionally, the tonometer and optomotry 
machines could assess ocular health.  While the ultrasound and MRI could image the 
eye and tumor in one field of view, MRI could capture the posterior chamber in more 
detail along with the extraocular space.  With different software programs, the tumor to 
eye ratio volume measurement were determined and compared to the gold standard of 
enucleation, embedding, serial sectioning and hand tracing.  It was found that there was 
a better correlation between the ultrasound and hand tracing histological sections.  
 
Concurrently, the tumor progression of six different genotypes was assessed.  
The tumor progression depended on the number and different genes deleted.  
Additionally, based on genotypes, it was determined there was not a strong genotypic 
trend in the increase in IOP or the loss of vision.  From the studies of tumor progression 
v 
we have learn more about the influence of genes on tumor progression, which will 
benefit additional genetic studies in mouse model systems and human tumors. 
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CHAPTER 1. INTRODUCTION 
 
 
1.1 ANATOMY OF THE EYE  
 
 The eye, a sensory organ, has been a useful model in the study of the vertebrate 
central nervous system (CNS) and its associated diseases [2].  It can be divided into 
three layers: the outer, middle and inner (Fig. 1-1).  At the front of the eye is the outer 
layer, which is composed of fibrous connective tissue that is further divided into the 
sclera and the cornea [2, 3].  The primary function of the sclera is to support the eye, 
while the cornea is responsible for the transmission of light through the pupil.  The 
middle layer, known as the uvea, is composed of the choroid, ciliary body and iris [2, 3].  
The iris is a smooth muscle at the front of the eye and is responsible for light regulation 
into the eye.  Following these muscles is the ciliary body that supports the lens and 
helps secrete aqueous humor fluid.  The choroid, at the posterior section, prevents 
reflection of the light and is responsible for the exchange nutrients and oxygen.  The 
innermost layer of the eye, the retina, is where incoming light is transferred into 
electroimpulses [2, 3].  These action potentials travel by the optic nerve to the brain, 
initially to the lateral geniculate nucleus (LNC) and finally to the primary visual cortex [2]. 
 
 When light enters the cornea the vision process begins.  Light continues to travel 
through the cornea, pupil, lens, vitreous humor and finally reaches the retina.  This final 
complex layer is composed of seven cellular groups [2, 3] (Fig. 1-2).  The ganglion cells 
are the first cell layer, where the initial light contact occurs, followed by the amacrine 
cells, bipolar cells, horizontal cells and photoreceptors.  These final neurons, rod and 
cone cells, are the most commonly referred to because they are responsible for the 
photochemical reaction, converting light into electroimpulses.  Each cell type has a 
specific role in sight [3].  Covering the majority of the retina, the rods are responsible for 
vision in low-light conditions.  Contrary, the cones, fewer in number, function in bright 
light conditions and help distinguish the visual acuity in the special concentrated region 
called the fovea. 
 
Vision is supported by many accessory structures in the ocular orbit. These 
include various muscle groups, a conjunctiva sac and vascular systems [2, 3].  Six 
external muscles that help search the visual field and track moving objects are divided 
into two main groups, the rectus and oblique [2].  The rectus muscles are further divided 
into the superior inferior lateral and medial.  These muscles are responsible for moving 
the eye horizontally and vertically.  Similarly, the oblique muscles, superior and inferior, 
are responsible for diagonal movement.  Each group plays a role in viewing the entire 
field. 
 
The conjunctiva sac and the vascular system are responsible for protecting and 
maintaining the eye [2, 3].  Located around the exterior globe is the conjunctiva 
composed of a thin epithelial membrane attaching to the lids and cornea epithelium 
creating a sac.  Along with protecting the eye with mucus, it has an active role in repair 
[3].  The vascular system exchanges, either indirectly or directly, the nutrients and gases 
for the entire eye [3].  It is uniquely divided into two separate systems, the retinal and 
uveal vessels and arranged to avoid interference with the transmitted light [3].  
Interestingly, the retina circulatory system is complex.  The inner retina is directly  
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Figure 1-1. Anatomy of the Human Eye. 
In the posterior chamber of the eye there are many layers.  The small box represents the 
order of each tissue layer.  Modified with permission.  Dyer, M.A. and R. Bremner, The 
search for the retinoblastoma cell of origin. Nat Rev Cancer, 2005. 5(2): p. 91-101 [4].  
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Figure 1-2. The Cellular Layers of the Eye. 
There are seven cell types in the eye beginning in the anterior chamber with the 
ganglion, amacrine, Muller, bipolar, horizontal and rod and cone cells.  Modified with 
permission.  Dyer, M.A. and R. Bremner, The search for the retinoblastoma cell of origin. 
Nat Rev Cancer, 2005. 5(2): p. 91-101 [4].  
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nourished by vessels, where as the outer part, including the photoreceptors, are 
nourished by diffusion.  All three of these accessory structures are necessary and 
responsible for the movement, repair of the eye and exchange of nutrients.   
 
In addition to the orbital supportive structures, intraocular fluid and its movement 
support the interior globe.  Both the anterior and posterior chambers are filled with either 
aqueous humor or vitreous [3].  Movement of these fluids ensures additional exchange 
of nutrients [5].  The vitreous is a gelatinous protein rich fluid [3].  This static fluid is never 
replenished or renewed.  On the other hand, the aqueous humor is secreted by the 
ciliary bodies and moves through the pupil into the anterior section of the eye.  Here the 
canal of Schlemm drains it into the vascular and lymphic systems to maintain the eye 
pressure [3].  It maintains the eye pressure.  If the flow is disrupted, fluid can accumulate 
resulting in increased intraocular pressure and decreased nutrient exchange, eventually 
leading to visual damage.  
 
 
1.2 RETINA DEVELOPMENT  
 
The retina is thin layer of tissue, composed of multiple cellular layers, that carries 
out the function of sight.  The seven layers are divided into three cellular nuclear layers, 
the outer nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL) 
and two synaptic layers, the outer plexiform layer (OPL) and inner plexiform layer (IPL) 
[6-8].  At the posterior part of the eye, the ONL is composed of photorecepter cells, rods 
and cones.  These neurons send their impulses to the INL, bipolar cells.  Additionally, 
the horizontal and amacrine cells also play an essential role by directing the signal to the 
GCL where the ganglion and amacrine cells are located.  The ganglion cells transmit the 
output electric impulses to the correct locations in the brain. 
 
Each of the cell populations originates from multipotent progenitor cells, which 
can give rise to any one of these seven cells [9, 10].  In the early stages of eye 
development a newly postmitotic cell line migrates to the proper location where it further 
differentiates.  For a progenitor cell to complete this process different intrinsic changes, 
such as expression of transcription factors, make it “ready”, or competent [9].  Once 
competent, the cell is able to respond to additional external cues [9].  Both play a role to 
ensure a particular certain cell type is born.  Interestingly, these transitions occur at 
specific developmental times, leading to a conserved birth order [6, 7].  For example, 
ganglion cells are always the first to develop, followed by cones, horizontal cells, 
amacrine cells, rod, Müller Glia and finally bipolar cells [7].  Interestingly, Cepko and 
colleagues found a cell!s fate is based on the last day it went through S phase [9].  Once 
a cell is committed as one type it cannot revert to a previous cell population [9].  If the 
proper external and internal signals are present the subsequent linage continues to 
develop [9, 10].  As expected cellular proliferation is tightly regulated to ensure the 
proper ratios of each cell type guaranteeing proper visual signals and function.  
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1.3 CELL CYCLE AND THE IMPORTANCE OF ITS REGULATION IN NEURAL 
DEVELOPMENT  
 
 The regulation of the cell cycle ensures that the proper cell numbers are present 
for each tissue and organ.  The cell cycle can be divided into two different phases, 
interphase and mitosis.  Interphase prepares the cells for division. It is further divided in 
G1 phase, where proteins and organelles are duplicated, S phase, where chromosomes 
are duplicated and G2 phase, where the remaining proteins needed for mitosis are 
synthesized.  During mitosis the cell divides the chromosomes, organelles and 
cytoplasm equally between the two daughter cells.  The four stages, prophase, 
metaphase, anaphase and telephase, ensure this proper duplication.  Upon dividing the 
cell exits the cycle.   
 
Multiple cell cycle proteins play essential roles in cellular division.  In a non-
dividing cell the retinoblastoma protein (Rb1) binds to E2F transcription factors, which 
are responsible for the transcription of additional genes required for transition to S 
phase.  To date there are five E2F proteins (E2F1-5) and two additional Rb family 
members, p107 and p130 [11].  Each E2F member has a preference to bind to one of 
the Rb family members [12].  Interestingly, these cell cycle regulators have similar 
pocket domains, thus are referred to as the “pocket family” [13].  These proteins differ in 
their expression patterns throughout the cell cycle.  For example, p107 is highly 
expressed in cycling cells and p130 is expressed at high levels near the exciting of the 
cycle [12].   
 
The most well studied player of this group is the retinoblastoma protein Rb1.  Its 
phosphorylation status was the first linked to the cell cycle.  Once phosphorylated, by 
cyclins and cyclin dependant kinases, Rb1 losses its high affinity for the E2F protein and 
thus the cell becomes committed to divide.  Once the cell finishes replication and exits 
the cell cycle and Rb1 gets hypophosphoralated allowing it to once again bind to E2Fs.  
If any of these proteins are not properly regulated, uncontrolled cellular division occurs 
and leads to an increase differences in cell number affecting the organs function or 
generates a mass leading to potential cancers [13].   
 
As previously mentioned, a well-coordinated and fine-tuned cell cycle is important 
for maintenance, but also developmental stages.  During different periods cellular 
intrinsic proteins help regulate the cell!s competence to differentiate [9].  If these proteins 
are interrupted, the cell competence changes, ultimately affecting the cell population and 
subsequent groups.  For the eye, this can affect different cell types based on the linear 
birth order [9].  Thus, if earlier cells are increased, then the late population will be 
decreased which could affect the electroimpulse transmission and affect vision. [9].  
Ultimately these changes can lead to pathological conditions, such as retinal 
degeneration and tumor formation, called retinoblastoma [14]. 
 
 
1.4 MOLECULAR ASPECTS OF THE RETINOBLASTOMA GENE AND PROTEIN  
 
 The discovery of the RB1 gene was first localized to chromosome 13q14 and 
cloned in 1986 [15, 16].  It spans a region of 27 exons and is conserved across many 
different species [7].  The gene encodes for Rb1 protein, which is 105 KD and is best 
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known for its role in cell cycle regulation [17, 18].  In an hypophosphorylated state, this 
tumor suppressor binds to E2f transcription factors to prevent excessive cell division 
[10].  However, when Rb1 is phosphorylated it!s structure changes and the transcription 
factors are released to active genes needed for cells to pass through the G1 checkpoint.  
As the cell finishes the cycle and approaches the mitotic phase Rb1 is dephosphorylated 
to its original hypophosphorylated state.  When there is a mutation in this tumor 
suppressor the cell can cycle out of control leading to a potential malignant growth.   
 
Various types of mutations, such as point mutations, small deletions and 
insertions, occur in the RB gene leading to a frame shift or a premature termination [10].  
These changes inactivate the Rb1 protein.  When the protein!s mutations were further 
investigated a loss of heterozygosity (LOH) was originally seen in the childhood disease; 
however this concept was further seen in other cancers, such as lung, bladder, brain and 
liver cancer [19, 20].  Interestingly, the somatic or germline mutations in the same gene 
can lead to different tumor types and ages of onset. 
 
 
1.5 RETINOBLASTOMA THE DISEASE  
 
Retinoblastoma mutations occur prior to birth present in both of the disease 
forms, non-inherited and inherited.  The majority of disease cases, about 60%, are from 
non-inherited mutations [21].  The unilateral tumor begins with a single retinal cell 
acquiring two sporadic random mutations [22].  The remaining forty percent of cases are 
typically bilateral and caused by an inherited germline mutation in all cells of the body 
with a second somatic mutation in a retinal cell.  
 
From his observation in the seventies, the mathematician Alfred Knudson 
developed the well-known “two-hit” hypothesis.  He noticed children with bilateral 
retinoblastoma developed the disease earlier than those with the non-hereditary 
unilateral disease.  This early onset was attributed to the first mutation occurring in a 
germline cell in utero.  From these observations of retinoblastoma, the “two-hit theory” of 
cancer was born.  This finding was the launching pad for the general understanding of 
cancer and the retinoblastoma disease.  Shortly after this discovery, karyotype analysis 
revealed further detail that the insertional deletion was on chromosome 13 [17].  Further 
examination of cancerous cells found that both copies of chromosome 13 were the 
same.  This loss of heterozygosity (LOH) explained that this inherited mutation was 
recessive and when the cell had two copies, its proliferation was uncontrollable [17, 23].  
The discoveries in retinoblastoma continued to produce information about the 
commonalities of cancer.  With the retroviral gene transfer of a wild type RB gene, it was 
found that cells with the endogenous inactivation in the RB gene were rescued from their 
uncontrolled proliferation.  This experiment led to the definition of a tumor suppressor.  In 
addition to retinoblastoma cases, Harbour and colleagues found abnormalities in the RB 
gene in small cell lung cancer samples [24].  Since these discoveries, the RB gene has 
been found to be abnormal in many adult cancers. 
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1.5.1 Diagnosis modalities 
 
Retinoblastoma pathological effects are often confused with many other eye 
abnormalities.  It is usually first detected by observing the eye!s reflex to a bright light in 
a dimly lit environment.  A healthy child!s pupil reflexes red, but if a tumor is present the 
reflex will be a white or pinkish color [25]; however this reaction is difficult to distinguish 
from other diseases, such as leukocoria, toxocariasis, coats and cataracts.  Therefore, 
ophthalmologists and other pediatric specialists use combination of approaches with 
different modalities to further confirm the pediatric disease of retinoblastoma. 
 
The initial diagnosis is conducted with a retinal camera examination of the 
sedated child.  This allows physicians to examine the entire globe for tumors and 
potential tumor seeding.  This modality is sufficient for the initial diagnosis; however it 
has some limitations [26].  First tumor boundaries cannot be visualized in one field, 
limiting a comprehensive view of the tumor.  Second, tumors at the periphery and 
extraorbital space cannot be detected.  Third, the camera cannot be used for the more 
advanced cases, because tumor invasion in the anterior chamber obstructs the view.  
Taken together the retina camera can provide an assessment of ocular health, but 
cannot provide a conclusive evaluation, therefore further confirmation is necessary with 
other modalities. 
 
To complete the initial ocular health evaluation, additional exams with a rebound 
tonometer and visual acuity test are conducted.  The rebound tonometer detects 
changes in the eye!s pressure normative values.  Often the presence of a tumor can 
grow into the anterior chamber, press on the lens or tumor seeds can break off from the 
main mass and settle near the canal of Schlemm [26, 27].  Each event can lead to an 
increase in ocular pressure (IOP), which can damage the nerves leading to potential 
visual loss. 
 
In addition, the visual acuity determines the severity of the tumor and placement 
of the tumor.  A patient!s vision is typically monitored using a Sneal eye chart.  Often the 
placement of the tumor or ganglion cell damage interrupts the visual path and causes a 
decrease in vision.  While both visual acuity and eye pressure are more informative, the 
tumor!s stage is most effectively confirmed with additional imaging modalities. 
 
With the advancement of high resolution imaging modalities, such as 
ultrasonography, magnetic resonance imaging (MRI) and computed tomography (CT), 
tumor growth can be fully characterized.  These modalities are essential to determine the 
it!s growth patterns, such as endophytic, exophytic, or combination of both.  Generally an 
endophytic tumor invades the anterior portion of the globe, whereas an exophytic tumor 
invades the optic nerve and conjunctiva.  If the tumor grows into the extraorbital cavity, it 
is likely to metastasize to the brain, spinal cord, bone marrow, or spread into the lymph 
nodes [26].  These cases require aggressive treatment.  By combining the diagnostic 
abilities from each method a comprehensive picture of the tumor!s stage is diagnosed.  
 
Unlike the retina camera, ultrasound can be used to visualize the entire eye in a 
single field of view and its resolution of the anterior chamber and the retina!s periphery 
are very good.  Moreover, the power Doppler function can detect blood flow and 
echogenic debris in the vitreous [28].  In particular, vessels are detected by determining 
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the differences in sound wave frequencies between the vessels to the tissues.  This 
diagnostic can provide information about the tumor!s activity, such as nutrient exchange 
and waste elimination [28].  For example, a well vascularized tumor is likely to have 
better drug delivery compared to a tumor that is not well vascularized.  Unfortunately, the 
major limitation of this diagnostic tool is the depth that sound waves can travel and 
therefore imaging of the extreme globe!s posterior and invasion in extraocular space is 
difficult or impossible. 
 
Prior to the ultrasound, the traditional imaging modality for retinoblastoma was 
the computed tomography (CT).  It can detect intraocular, extraocular, intracranial 
spread and calcification of tumors [28].  However, it use is limited because radiation 
exposure to germline mutation patients is dangerous for the potentially to causing 
secondary tumors.  This limitation, along with the poor detection of infiltration in the 
choroid, sclera and optic nerve made this tool unattractive and it has been replaced with 
the magnetic resolution imager (MRI).   
 
With the development of the MRI the tumor can be viewed in various planes in 
the surrounding tissue environment such as: corneal, sagittal and transverse planes.  
This technology can clearly confirm the presence of the tumor, especially in the posterior 
chamber and brain.  In addition, different software programs can be used to monitor 
tumor size and its change with treatment.  Some researchers have suggested a 
correlation between the tumor size and the likelihood of tumor infiltration [29].  While the 
sensitivity is far superior to other diagnostic tools and continues to improve, MRI has 
some difficulty imaging tumor calcification and hemorrhages within the tumor [27]; 
however these limits are outweighed by its radiation free technology.  Using these high-
resolution image modalities helps classify the disease, decide about treatment options 
and monitor tumor response. 
 
 
1.5.2 Retinoblastoma disease classification 
 
Historically, there have been multiple different classification systems for 
retinoblastoma based on the available technology.  These classifications have been 
used to establish a baseline, determine treatment progress and aid in the communication 
between medical doctors and clinical studies.  The first system, and perhaps the most 
widely referred to today, is the Reese-Ellsworth (R-E1-5) classification.  Originally 
developed in the 1960s, it was used to classify intraocular tumors and track the success 
of external beam radiation therapy (EBR).  This system classifies the tumor!s size and 
location into five different groups (Table 1-1).  The tumor!s size is determined by 
measuring the circumference of the optic nerve!s head as a reference with the unit of 
measurement of disc diameter.  The first group (R-E 1) is the least advanced form of the 
disease.  In general, these tumors are less than 4 disc diameters and reside in the 
posterior globe; whereas the most advanced stage, R-E group 5, has massive tumors in 
over half of the eye and show marked vitreous seeding [30].  While this system is 
beneficial it only diagnoses the health of the globe.   
 
Overtime treatment options have changed and additional classifications were 
developed [27].  These systems classify the intra-retinal tumor along with invasion and 
metastasis into the extraorbital space, brain or other system.  Recently, Chantada and  
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Table 1-1. The Reese-Ellsworth Description of Salvaging the Eye. 
 
Classification group  Change of 
salvage 
Distribution of tumor  
Group 1-A Very favorable Solitary tumor, less than 4 disc 
diameter (dd) in size at equator 
 
Group 1-B  Multiple tumors, none over 4 dd in 
size, all at equator 
 
Group 2-A Favorable Solitary tumor, 4 to 10 disc diameter 
in size or behind the equator 
 
Group 2-B  Multiple tumors, 4-10 dd in size, 
behind equator 
 
Group 3-A Doubtful Any lesion anterior to the equator 
 
Group 3-B  Solitary tumors larger than 10 dd 
behind equator 
 
Group 4-A Unfavorable Multiple tumors, some larger than 
10 dd 
 
Group 4-B  Any lesion extending anterior  
Group 5-A Very Unfavorable Massive tumors involving over half 
the retina 
 
Group 5-B  Vitreous seeding 
 
 
Source: Reese, A.B. and R.M. Ellsworth, Management of retinoblastoma. Ann N Y Acad 
Sci, 1964. 114: p. 958-62 [30]. 
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colleagues were one group who proposed a system that allowed physicians to focus on 
the entire scope of the disease [31].  Their goal was to build comprehensive picture of 
the disease.  Both of these staging systems are examples of current methods in which 
physicians can communicate the treatment options for different clinical protocols.  
 
 
1.6 HISTORY OF CLINICAL TREATMENT  
 
In 1809 James Wardrop was the first to publish a retinoblastoma clinical article 
that suggested enucleation as the standard treatment for the tumor [32].  For nearly a 
century, this was only clinical treatment option.  It was Henry Stallard!s discovery of 
retinoblastoma!s radiosensitivity that lead to this less invasive treatment option [33]; 
however, it was not completely successful for all cases and often there was a 
reoccurrence of secondary tumors.  Alternative local treatments have been investigated 
throughout the years. 
 
It was not until the development of external beam radiation therapy (EBR) that a 
more successful direct and focal treatment was used [34].  This conservative focal 
treatment used radiation to locally target and limit the overall DNA damage.  While this 
treatment was more safe and effective, it had adverse side effects, such as skull 
malformations and secondary tumors, seen primarily in children less than 12 months of 
age [35, 36].  Today, EBR treatment is reserved for recurrent or sever cases of older 
patients of retinoblastoma. 
 
One way clinicians have addressed the limiting factors of EBR was to use 
chemotherapy agents.  Early in the 1950s Kupfer was first to establish retinoblastoma!s 
sensitivity to the chemotherapeutics, in particular nitrogen mustard.  Unfortunately, the 
overall long term response was not successful [37].  His work led to further exploration of 
other chemotherapies [36, 38, 39].  These studies have sparked interest in combining 
focal treatment with drug treatments [40, 41].  An important comparative study looked at 
tumor response to EBR verse EBR with the chemotherapy drugs, vincristine, etoposide 
and carboplatin (VEC) [41].  While this study showed promising results, the use of EBR 
had continued concern physicians [36, 42, 43]. 
 
Eventually the development of additional therapies, such as laser thermotherapy, 
cryotherapy, brachytherapy and chemothermotherapy, gave physicians more treatment 
options.  Each technique was specific to the tumor!s size and location of malignant 
masses.  Usually, laser photocoagulation, thermotherapy and cryotherapy are used to 
treat small tumors.  Laser photocoagulation uses a laser to coagulate a posterior tumor!s 
blood supply [26, 27].  Whereas tumors located in the peripheral, are treated with the 
cryotherapy freezing technique and thermotherapy, applies heat application to the tumor 
[26, 27].  However, if the tumor is too large and shows seeding it is managed with 
brachytherapy, a radioactive implant [44-46].  With these additional therapies the 
combinational treatment approach greatly expanded. 
 
These different treatments paved the way for continued combinational studies.  
Various studies explored the use of focal therapies with the VEC drug combination [41, 
47-49].  Of these studies, one reported a full ocular salvage of late stage retinoblastoma 
group [47].  Hence, ocular salvation and preservation of sight became possible for a 
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number of late stage retinoblastoma patients.  Even though the tumor response was 
promising, the long-term effects of these drugs were questionable.   
 
Several concerns mounted over the use of etoposide as it was suspected to 
cause the secondary cancer, acute myeloblastic leukemia (AML).  In 1998, it was 
reported that the pediatric population was at a special risk for developing this secondary 
cancer [50-54].  In response, one group developed a protocol where they treated 
children with the combination of carboplatin and vincristine for 8 courses.  In addition, 
they eliminated or delayed the use of focal therapies [55].  They found 60% of patients 
with early stage tumors had event-free survival for approximately 2 years [55].  
Unfortunately, only 30% of children with late staged tumors (R-E IV-V) responded.  This 
finding was similar to other reports of late stage tumor treatments.  Even though there 
was a lack of success with the advanced tumor population, it concluded to be a success 
for children with early-stage intraocular retinoblastoma [55].  The results of this study 
emphasized that treatment outcome was heavily dependent on the tumor!s initial stage. 
 
With poor results for advanced diseases, a new therapy was needed.  Therefore 
physicians explored other pediatric cancer treatments, in particular neuroblastoma [56, 
57].  It was found that the topoisomerase I inhibitor, topotecan, was effective for this 
childhood cancer.  Not only was it effective, but it could pass the blood brain barrier.  
These clinical findings were promising for retinoblastoma because the blood-brain barrier 
is similar to the blood-retinal-barrier protecting the eye.  This finding was further 
supported by additional preclinical xenograft studies for pediatric nervous system 
cancers and in particular an orthotopic retinoblastoma xenograft model that used 
topotecan or topotecan in combination with other anti-cancer agents [58-60].  The later 
found good response and penetration to the eye with intravenous injection [60].  While 
these results were exciting, the chemotherapies were administrated by i.v.  and thus 
there was a concern for the systemic exposure, especially for children with the germline 
mutation. 
 
While this study supported the possibility of reducing the chance of AML, 
physicians wanted to improve the amount of drug exposure to the eye and decrease 
systemic exposure.  It was thought a local delivery of the drug could lead to an increase 
in concentration; however, the eye structure proved to be challenging.  A direct 
intravitreal injection was not feasible because of the risk of damaging the eye and the 
possibility disseminating tumor cells.  Nevertheless, researchers circumvented this 
obstacle with by injecting in the surrounding orbital area [61-64].  Based on these 
studies, Abramson!s group conducted a clinical study which treated patients with only 
subconjunctival injections of carboplatin [65].  With this new technique, he found a 
decreased in systemic side effects and partial to stable tumor responses.  Unfortunately, 
there was still little success with the advanced tumors and the long-term prognosis was 
unfavorable [65, 66].  
 
This new technique and the findings of retinoblastoma!s sensitivity to topotecan 
led to additional therapeutic protocols.  In one trial, patients received topotecan, 
vincristine, focal therapy treatments and a subconjunctival treatment of carboplatin.  The 
current results are promising, but are being further being confirmed at St. Jude 
Children!s Research Hospital (verbal communication).  Similarly, an additional clinical 
trial focused on the subconjunctival injection of topotecan alone.  This was similar to 
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Abramson!s study in 1999, but it replaced carboplatin with topotecan [67].  While this 
study focused on toxicity, they also observed a partial response in six of the seven 
treated eyes [67].  While these recent clinical studies are exciting, further early phase 
clinical trials and animal studies with single agents or multiple drug combinations are 
needed to determine the ideal treatment and long-term effects. 
 
 
1.7 THE PHARMACOLOGY OF TREATING RETINOBLASTOMA  
 
To properly design preclinical and clinical studies the chemotherapeutics! 
pharmacologic properties need to be well defined.  It is essential to determine what the 
body does to the drug and how the drug affects the body, its organs and cellular 
receptors.  Before describing the pharmacology of the traditional retinoblastoma 
therapeutics, brief descriptions of general pharmacologic principles are essential.   
 
Pharmacology may be considered as two basic components, pharmacokinetics 
and pharmacodynamics.  When a drug is given, the body immediately starts to process it 
through a series of four pharmacokinetic steps: absorption, distribution, metabolism and 
elimination.  By characterizing each process a comprehensive understanding of the 
amount of drug reaching the therapeutic site is determined.  Drug absorption depends on 
the route of drug administration, such as oral ingestion or subconjunctival injection.  
Each site has unique characteristics in circulation and cellular characteristics, such as 
the number of membrane layers and cellular transport being either active or passive.  In 
addition, the drug!s biochemical properties, such as its aqueous solubility and its 
formulation or vehicle solution are factors that influence how the drug is processed [68].   
 
Once the drug is dispersed to different organs and cellular fluids, its distribution 
throughout the body continues to be heavily dependent on the chemotherapeutics! 
physiological and physicochemical properties.  In particular, regional blood flow has a 
large impact and quickly moves drug to major organs.  Organs! membrane transporters, 
such as transporters efflux uptake and influence their exposure.  Similarly, capillary 
permeability, intracellular and extracellular pH gradients and plasma proteins can affect 
the amount of free drug to cross cellular membranes throughout the body [68]. 
 
 The third phase of a drug!s pharmacokinetics is the metabolic conversion into 
metabolites, which typically ceases its activity; however, the exception to this is seen 
with prodrugs.  These drugs are synthesized to become active when exposed to 
metabolic enzymes.  In both of these cases different enzymatic systems carry out 
changes to the drug!s structure, typically occurring in the liver [68].  After the drug!s 
distribution, they are eliminated from the body. 
 
 The drug!s elimination or clearance occurs primarily in the kidney, but can also 
occur by other routes, such as the liver and GI tract [68].  This last phase is important 
and highly dependent on an organ!s function or developmental state.  If either of these 
cases is abnormal, toxicity may occur.  Elimination can be monitored in the clinic prior to 
drug dosing.  For example, renal function is determined prior to dosing the 
chemotherapeutic carboplatin to avoid systemic toxicity. To fully understand a drug!s 
pharmacokinetics the overall health of the clearance organs and the previous three 
phases are established and closely followed.  
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The understanding of a drug!s pharmacokinetics is only one component to its 
pharmacologic fingerprint.  Equally important is the drug!s pharmacodynamic properties 
or its effects, such as the physiological effect and the mechanism of action, on the body 
or tumor.  Typically drug targets are diverse.  They can include receptor proteins, such 
as transcription factors, enzymes in a regulatory pathway, proteins involved in structure 
of the cell or even nucleic acids [68].  Drug binding to their target can lead to many 
cellular changes and to its ultimate response.  By determining the pharmacokinetics and 
pharmacodynamics of a drug, the most effective and rational therapeutic use can then 
be translated from preclinical studies to clinical trials. 
 
Etoposide was first synthesized in the1960!s and surprisingly it took over thirty 
years for the FDA to approve the drug for the treatment of a number of cancers, such as 
lung cancer, non-Hodgkin!s lymphoma, leukemia, Kaposi!s sarcoma, neuroblastoma, 
retinoblastoma and various soft-tissue sarcoma [69, 70].  Due to solubility problems a 
prodrug, etoposide phosphate (Etopophos), was generated.  Even in its new form, the 
protein binding is surprisingly high, about 90%, which greatly limits the drug!s 
concentration [71].  Prior to its elimination, etoposide is cleared by both the kidney and 
liver, where its partially metabolized into inactive forms.  While the pharmacokinetics 
were rapidly understood and explained how the drug was processed, its mechanism of 
action was not immediately known. 
 
About one year after etoposide!s approval, its target, topoisomerase II, was 
characterized.  This enzyme creates a transient double strand break when bound 
covalently to DNA allowing the passage of nucleic acid segments through the break, 
thus regulating the over or under-winding of the DNA.  The function of topoisomerase II 
is essential in all processes involving DNA, but plays a large role in the S to G2 phase 
transition [54].  When the drug is present, it prevents the release of the enzyme from the 
DNA resulting in an increase in the number of transient complexes [54].  The ternary 
complex inhibits the DNA religation, which in turns caused the lesions to be permanent.  
Over time an increase in DNA strand breaks lead to apoptosis. 
 
As with most cytotoxic chemotherapeutic agents there are a number of acute to 
mild side effects, including alopecia, nausea and bone marrow suppression (the dose 
limiting toxicity) [54, 71].  While these side effects can be managed, disturbing 
complications of secondary cancers arose in children one to five years after treatment.  
Several groups reported a number of cytogenetic abnormalities responsible for the acute 
non-lymphocytic leukemia (ANLL) [51, 72, 73].  For the pediatric population, this side 
effect caused physicians to seek out other potential drugs for retinoblastoma.   
 
An additional topoisomerase interactive drug, a synthetic analog of camptothecin, 
topotecan (Hycamtin) was investigated.  Over the years, it has been used to treat many 
malignancies, such as sarcomas, nervous system and ovarian cancers [74].  It exists in 
two forms: the lactone (active drug) and carboxylate (inactive drug) [75].  The common 
toxicities are bone marrow suppression.  They range from mild to acute, such as 
alopecia, nausea, fever, anemia, thrombocytopenia [76].  When administered 
intravenously, its metabolism begins in the plasma by a non-enzymatic hydrolysis.  Its 
half-life has been reported to be approximately 2.5 hours [74].  Normal renal function is 
needed for rapid clearance from the plasma [74].  Uniquely, the bioavailability of the drug 
is not strongly influenced by the plasma proteins, with less than 20-50% of drug binding. 
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This makes it a perfect candidate for the treatment of different diseases of the central 
nervous system, such as the ocular system [74].  
 
Topotecan is primarily a S-phase inhibitor and therefore heavily dependent on 
the administration schedule.  Its target is the enzyme receptor topoisomerase I.  
Typically, this enzyme binds covalently to DNA, nicking a single strand of the double 
stranded helix allowing the nicked strand to rotate about the covalently held strand, thus 
relieving torsional strain on the DNA [76, 77].  This process is very important during DNA 
replication, as there is a constant need for unwinding and rewinding the DNA ahead of 
and behind the replication machinery. Topotecan targets the enzyme-DNA intermediate 
by reversibly binding and stabilizing the covalent complexes [76, 77].  During DNA 
replication, advancing replication forks collide with the stabilized complexes, which 
ultimately results in cell death [76, 77].   
 
Another commonly used drug to treat retinoblastoma is the antineoplastic 
alkaloid, vincristine (vincristine sulfate).  It is one of the chemotherapeutic drugs and has 
been used extensively to treat a variety of cancers, such as lymphosarcoma, Hodgkin!s 
and lymphoblastic leukemia [78].  This drug is widely used because it has limited 
myelosuppressive effects and therefore can be combined with many different therapy 
regimens, such as the VEC protocol commonly used in retinoblastoma.  While it has little 
to no effects on cell number of the blood, but it is known to cause neurotoxicity [78, 79].  
 
As with many chemotherapeutic agents, vincristine is cell cycle specific by 
blocking cells in mitosis phase.  Its mechanism of action is to bind tubulin proteins 
preventing the subunits from polymerizing into microtubules [78-80].  This interruption in 
structure affects the mitotic spindle, which is responsible for proper segregation of the 
sister chromosomes.  This leads to cellular arrest in metaphase and eventual cell death 
[80]. 
 
The pharmacokinetic properties of this drug are known primarily because of the 
more recent performed with sensitivity and specific bioavailability techniques.  With 
vincristine knowledge of the patient!s hepatic function is important to avoid toxicity.  This 
is because vincristine!s metabolism occurs in the liver and its metabolites are excreted in 
the bile [79, 80].  The drug is strongly influenced by the liver and thus as a fairly long 
half-life [79, 80]. 
 
Carboplatin is another anti-cancer drug often used for retinoblastoma therapy.  
Unlike the previously mentioned drugs, it is not dependent on the cell cycle.  Its 
mechanism of action causes cell death by adding platinum adducts to DNA creating 
cross-linkages between intra/inter strands of DNA [81].  Once it is added the platinum 
binding is irreversible and leads to cell death.  The disposition of the drug is not affected 
by the binding of plasma proteins [81, 82].  Prior to being eliminated in the urine, its half-
life is approximately 2-6 hours and heavily dependent on renal function.  
 
Unlike other platinum agents, such as cisplatin, carboplatin is less nephrotoxic 
[81-83].  Like many anti-cancer drugs the dose-limiting toxicity is myelosuppression, in 
particular thromcytopenia [81, 82].  Given these mild toxic effects, this anti-cancer drug 
has been used to treat many different cancers, such as ovarian, cervical, head and neck 
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and non-small cell lung [84].  To date carboplatin is among the four commonly used anti-
cancer drugs used in treating retinoblastoma. 
 
 
1.8 PHARMACOLOGY CONSIDERATIONS  
 
Retinoblastoma is a disease of the posterior chamber in the eye.  Like many 
diseases beyond the globe!s equator, its tumor!s location has presented 
ophthalmologists with unique treatment challenges.  While there are many routes to 
deliver drugs to the eye, such as systemic injection, topical treatment, intravitreal and 
periocular injections, each has unique limitations and risks [85, 86].  The systemic 
administration of chemotherapeutic agents has been explored early in the treatment of 
retinoblastoma.  The major side effects are systemic toxicity and unnecessary exposure 
to the non-target tissues.  This can be detrimental for children with germline mutations in 
Rb1.  Moreover, studies have shown that drug exposure is greatly reduced before it 
reaches the eye.   
 
The alternative delivery option is topical treatment, but it too has limitations, such 
as not reaching effective therapeutic levels in the posterior chamber [85, 86].  This is 
largely due to the blood-aqueous-barrier (BAB).  The ciliary body and iris epithelium form 
cellular tight junctions and the iris!s blood vessels prevent the exchange of most fluids, 
except those that are lipid-soluble [5].  Since both methods lead to inadequate amounts 
of drug delivery to the posterior chamber, ophthalmologists have searched for alternative 
local delivery techniques, such as intravitreal and periocular injections.  Intravitreal 
injections were found to expose the eye to a greater drug concentration, but its invasive 
nature poses a risk in damaging vision.  For retinoblastoma cases, this technique is 
especially dangerous because it could cause tumor dissemination.  Therefore periocular 
injections, such as subconjunctival, have been explored extensively for this pediatric eye 
cancer [86].  The location of the injection is less invasive and typically does not cause 
vision damage.  As previously mentioned, Abramson was the first physician to explore 
this method in a pediatric clinical study and found it to increase the drug concentration 
while lessening systemic exposure [65]. While the subconjunctival injection is a good 
option, it has many pharmacological challenges in the transscleral delivery, such as fixed 
physical and active barriers.  
 
The many ocular membrane barriers serve as a protective mechanism, but cause 
obstacles in vitreal drug delivery.  The conjunctiva, the first tissue, is a membrane with 
tight cellular junctions between adjacent cells.  This limits the transport of solutes based 
on their molecular weight and radius [87].  Typically the human conjunctiva is 30-fold 
more permeable to drugs than the cornea and thus may be better than topical 
application [88].   In addition, its large surface area aids in the absorption of drugs [87, 
88].  Once a drug has successfully passed out of the conjunctiva it encounters the globe 
and its primary protector, the sclera.  The sclera!s high permeability and porosity allows 
the diffusion of a range of solutes [89, 90].  Similar to the conjunctiva, it also provides a 
large surface area for absorption [89].  Once in the globe the drug next encounters a 
series of layers: the choroid, Brach!s membrane and blood-retina-barrier (BRB).  As with 
the previous tissues, the choroid also has molecular size and weight exclusion limits, 
which are species specific [91].  For example, one study found hydrophilic compounds 
had an inverse correlation between molecular weight and permeability in both bovine 
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and rabbit tissues [16].  In addition, it has been found that the choroid is more permeable 
than the following than Brach!s membrane and the retina pigmented epithelium [16].   
 
This final barrier is composed of many layers and referred to as the BRB, which 
is highly complex in drug transport.  Experiments comparing this tissue to the sclera 
have found it is a tighter barrier for hydrophilic, large molecules drugs [16].  The inner 
layer is largely composed of the endothelial cells from retina vessels [16].  The BRB is 
composed of retinal pigmented epithelium and is often compared to the blood brain 
barrier (BBB) [92].  The BRB is further divided into the inner (i-BRB) and outer (o-BRB) 
layers [5, 93].  The latter division, o-BRB, is responsible for protecting the neuronal retina 
from the free diffusion of xenobiotics from the circulating blood and the retina.  Its retina 
capillary endothelial cells form tight junctions and are surrounded by supportive cells [5, 
93].  They are not very permeable to hydrophilic substances, but more so to hydrophobic 
substances [16].  Based on the location, these capillaries are difficult to study, like the i-
BRB.  This sub-division is made of the cellular tight junctions of the retinal pigment 
epithelium (RPE) cells, which prevents free passage of molecules from choroid to the 
retina.  In addition it has a high level of melanin protein that potentially binds to the drug 
decreasing its concentration [91, 93].  Along with providing the physical barrier, these 
divisions also provide many active barriers, such as the blood, lymphatic vessels and 
drug transporters. 
 
A drug!s concentration can be immediately decreased after a subconjunctival 
injection largely due to the extensive blood and lymphatic system draining into the 
systemic circulatory system [85, 86, 91].  In addition, the episcleral veins, between the 
conjunctiva and sclera, are a potential obstacle [5, 85].  Once in the globe the drug 
passes to the choroid.  Due to its enormous blood volume flow, the choroid poses the 
most significant threat on transscleral delivery [5].  Finally the drug reaches the vitreous 
where its static gelatinous environment does not threaten the drug!s concentration.  In 
addition to contending with these fluid obstacles, the drug encounters multiple 
transporters at each layer or barrier system. 
 
Along with passive diffusion, active transport plays a key role in transscleral 
delivery.  In general, drugs move into the vitreous by passive diffusion when the 
concentration is high or when the active transporter proteins are over saturated [16]; 
however, this is highly dependent on the drug!s physicochemical characteristics.  There 
are a number of active transporters in the eye!s tissues that protects it from foreign 
compounds and can complicate drug delivery.  The expression of transporters largely 
impacts the amount of drug, which reaches the ocular space.  To date there is no 
comprehensive picture of the different transport proteins in ocular tissues.  The current 
information is a collage from recent experiments, such as in vitro studies, cell culture 
work and tissue explants, with multiple species (Appendix A).  For a drug to 
successfully pass to the vitreous it encounters many drug transporters in the posterior 
region and there is minimal understanding about their expression in these tissues.  To 
date seven different transporters have been localized to this area of the eye and include 
P-glycoprotein (P-gp), organic cation transporters (OCT), the multidrug resistant proteins 
(MRP1), the organic cation transporters (OCT3), organic anion transporting polypeptide 
(OATP-2 and OATP-E) and breast cancer resistance protein (BCRP) [16, 87, 94].  While 
all of these transporters are well established in other tissues, their presence in the eye 
are still largely under investigation.  As more information is gathered, it is important to 
 17 
remember the factors of species variation and ontogeny of expression. Therefore, a 
summary of the possible effective transporters in the eye needs to be appreciated in 
pharmacokinetic studies. 
 
 
1.8.1 Preclinical trials 
 
1.8.1.1 Previous rodent models 
 
Typically clinical trials are designed based on previous clinical and preclinical 
studies, which are important for determining the initial toxicity of single and 
combinational therapies.  However, if the animal model does not recapitulate the human 
disease preclinical the results are difficult to interoperate.  Over the years the 
development of more relevant animal models have lead to more accurate translation of 
preclinical studies to early phase clinical trials.   
 
Shortly after Knudson!s “two hit” hypothesis of retinoblastoma, there was much 
advancement in the field; however, the attempts to generate an ideal retinoblastoma 
model system were a continued challenge.  The first models were created by a 
heterotransplantation of retinoblastoma cells in adult athymic “nude” mice [95].   From 
this study they transplanted fresh retinoblastoma tumor into the anterior chamber of the 
eye.  Unfortunately, the tumors were avascular and no tumor extension into the 
extraocular cavity was seen.  An alternative model was generated in rats when the 
human adenovirus plasmid was injected in newborns [96].  Ironically this model 
generation of this model was an accident.  Their original goal was to develop pituitary 
adenomas with a SV40 Tag viral oncogene.  This first viral induced retinoblastoma 
mouse was the launching pad for other groups to develop models with retina-specific 
tumors. 
 
The first viral induced tumor mouse was generated shortly after and provided the 
foundation for other groups to develop retinoblastoma models [97-99].  In particular, 
researchers took advantage of the ocular promoters expressed at different 
developmental stages and locations.  The first was generated with the promoter of the 
interphotoreceptor retinoid-binding protein (IRBP) gene [100].  In brief, the vector was 
designed using the IRBP promoter with SV40 Tag oncogene.  While these animals 
developed tumors very young and in the outer retina, their histology indicated that the 
tumor arose from the entire photoreceptor layer.  This was due to non-specific binding of 
the SV40 Tag to many cellular proteins, such as pRB1 and p53 [100].  This problematic 
design was corrected by targeting Rb1 specifically with a construct made of the alpha 
crystallin promoter and the human papillomavirus (HPV) E7 oncogene [101]; however, 
this model was unsuccessful because the rodents! lens developed abnormally and there 
was additional onset of epidermal cancers.  Thereafter, Mukai and colleagues created a 
retinoblastoma mouse with a specific IRBP promoter with E7 and found tumors [102].  
Unfortunately, their tumors were not specific to the neural retina and developed in the 
retinal pigmented epithelium and ciliary body [102].  Research continued to struggle with 
creating the ideal preclinical model for this pediatric cancer.  
 
After the full characterization of the RB gene and the advancement of genetic 
mouse models, there was great excitement to create the “knockout” mouse from 
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embryonic cells with the mutated RB1 gene [103-105].  When researchers knocked out 
both copies of RB, embryonic lethality occurred.  And when they created the 
heterozygous RB1 (+/-) mouse it never developed retinoblastoma [103, 105].  This was 
unlike the human cases where a single germline mutation leads genetic instability, loss 
of heterozygosity eventual ocular tumor.  Following this surprise, researchers specifically 
targeted the RB gene in the cells of the retina to avoid embryonic lethality; however, the 
eyes were still tumor free [106, 107]. 
 
Advancing molecular genetic tools led to the valuable Cre-lox system, which 
made it possible to study embryonic lethal genes in adult animals [108].  Briefly, this 
recombination system targets a specific sequence of DNA with the Cre recombinase 
bacterial enzyme.  This recombinase recognizes the inserted “lox” sequences and 
excises DNA.  This results in the removal of an essential gene or sequences in the gene.  
This novel system provided the tools to generate an adult mouse lacking an intact RB 
gene.  Various models were generated using this system and driven by specific 
developmental retinal promoters, Nestin, Chx10 and Pax-6 [103-105].  Much to 
scientists! dismay these mice were still tumor free and thought to be due to species 
variation.   
 
Later studies suggested this phenotype difference could be due to the role of 
other RB family members compensating for the loss of Rb1 specifically in the mouse.  
The final breakthrough occurred when the RB1lox/lox mouse was crossed with the 
knockout p107 mouse.  Retinoblastoma tumors developed and their offspring were 
breedable [103-105, 109, 110].  In addition, it was found that retinoblastomas could 
developed when the RB1lox/lox mouse was mated with the knockout of the other pocket 
protein, p130 [111].  Taken together, the development of these model systems have 
aided in the advancement in of understanding retinoblastoma disease progression and 
conducting relevant preclinical trials. 
 
An additional successful model system is the orthotropic retinoblastoma 
xenograft rat.  This model was generated by injecting the human retinoblastoma cell 
lines, Y79, Weri or Y79-luciferase, into the vitreous of newborn rats, which are immune 
naive on the first day of life [60, 112, 113].  Unlike previous nude mouse models, the rats 
have an intact immune system, which allows for comprehensive drug studies.  In 
addition, the ocular environment is still developing and allows for the study in the 
appropriate temporal environment.  The major advantage is that the tumors developed 
within only two weeks, thus providing a rapid way to study tumor growth and preclinical 
drug combination therapy [60, 112, 113]; however, there are some drawbacks.   The 
tumors were generated from these human cell lines in a developing rat ocular 
environment, are not sporadic and grew too rapid for long-term study.  Nonetheless, this 
model continues to be beneficial when used in combination with genetic mouse models, 
especially for carrying out preclinical studies.  
 
1.8.1.2 Summary of preclinical trials 
 
The use of animal models, such as rodents, are important in understanding the 
tumorgenesis, genetic mechanisms involved in cancer and are key for preclinical 
studies.  Ideally preclinical trials provide information for human clinical trials.  Over the 
years the majority of preclinical studies have been done with the LHbeta-SV40 Tag 
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retinoblastoma mouse.  These models have allowed for rapid study of drug 
combinations.  These preclinical studies have included vitamin D analogs, attenuated 
viral treatments, focal therapies, combinational therapies and traditional retinoblastoma 
chemotherapeutics, chemotherapeutic agents and viral treatment [114-116].  While 
these treatments showed some tumor response, toxicities were often seen as well as the 
lack of complete tumor control.   
 
Over the years there have been many unique approaches to preclinical 
treatments.  There were two studies in the nineties that used vitamin D or its analogues 
[115, 117].  This therapy was based on the finding of calcium receptors on 
retinoblastoma tumors.  While this was a unique and creative treatment possibility, the 
animals experienced a lot of toxic side effects and death.  An additional alternative study 
included the use of attenuated viruses or viral gene therapy.  Brandt and colleagues 
explored the use of the herpes simplex virus type 1 to deliver the gene [114].  The 
researchers reported this treatment to be successful in other nervous system cancer 
cases.  When retinoblastoma tumors were targeted with this treatment their initial 
response was promising, but the long-term effects were not.  More recently an 
alternative preclinical trial with AVV-virus gene-therapy was used to deliver interferon-
beta to tumors with intravitreal injections [112].  Previously, interferon-beta was reported 
to have anti-tumor properties.  Researchers found retinoblastoma to respond well and 
suggested this treatment to be used in conjunction with other systemic therapies.  One 
drawback is the use of intravitreal injections in retinoblastoma cases because there is of 
the risk of tumor dissemination.  With the potential risk of tumor spread, researchers 
have explored other focal treatments and subconjunctival treatments with standard 
retinoblastoma chemotherapeutics.   
 
Similar to the clinical trials, there have been many reports studying the use of 
focal therapy treatment, such as EBRT and cryotherapy, alone or in combination with 
chemotherapy treatments or chemotherapy alone in the large T antigen mouse model 
[64, 118].  From these studies it appeared that the combination of focal therapy and the 
combination of carboplatin with EBRT had the most success.  Additionally, preclinical 
studies using chemotherapy alone have generally found a 50% response or greater with 
subconjunctival injections of topotecan, carboplatin liquid, nanoparticle or carboplatin 
fibrin sealant [119, 120].  While these preclinical studies have shown potential promise, 
there were some influential factors not considered.   
 
 The majority of these studies was conducted in a short time frame and used the 
beta-subunit SV 40 large T-antigen retinoblastoma mouse models, which has many 
shortcomings.  The first drawback was that the tumors were not of the correct genetic 
RB lesions.  Second, retinoblastomas at different stages of development were not 
studied and the most influential disadvantage was the fact that the large T antigen 
nonspecifically binds to other oncoproteins, such as the tumor suppressor p53 [100].  
While no preclinical study can be perfect, the use of other preclinical models that 
recapitulate the human disease would allow these studies to be more readily translated 
to the clinic.  
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1.8.2 Challenges in conducting these studies 
 
While animal models give researchers much insight to the disease and its 
potential treatments, there are many challenges in conducting pharmacological 
experiments in preclinical models.  The first challenge is the model system, both 
xenograft and transgenic mouse model.  Xenograft models have many limitations, which 
revolved around the injection of highly passed cell lines in a non-native location of an 
immune compromised animal.  All of these factors can potentially influence tumor 
response to treatment.  A better alternative is transgenic mouse models.  While they are 
often more acute in their disease presentation and location, their genetic changes can 
alter pharmacological responses, especially if the change occurs in every cell in the body 
or if the gene is driven by a non-native promoter [121].  While these challenges do exist, 
they can be mitigated in using multiple model systems and control cohorts.   
 
The second and most challenging aspect is converting the dosage between 
different species.  To do this calculation, two different methods, body surface area (BSA) 
and area under the curve (AUC) are used.  Currently, the clinic uses body surface area 
as the standard to determine the drug dose [122].  This method was originally developed 
by an intensive preclinical study that found oxygen, caloric expenditure, organ size and 
function were similar across many species! body surface area [122].  Although BSA has 
provided to method in determine dose, its major drawback is the inability to account for 
interspecies difference in absorption, distribution and/or elimination parameters [123].  
By ignoring these essential components, it is likely to over or under dose, which can 
potential lead to a reduced therapeutic result and potential chemotherapeutic resistant 
population.   
 
The alternative is to determine the dose by using equivalent AUC values.  AUC 
guided dosing, which accounts for these biological processes of different species.  To 
determine the AUC, pharmacokinetic studies are conducted.  Measuring the drug 
concentration at many time points and plotting these as concentration verse time.  By 
determining the AUC, the clearance rate, metabolism, protein binding and ultimate drug 
exposure, are all taken into consideration in the final dosage.  This value can be used to 
compare the animal exposure to human exposure enabling the rational selection of drug 
dosage.  
 
The major drawback to using the BSA or AUC guided dosing is that not all 
studies can be easily compared.  This is largely due to the limitation and ethical 
constraints of clinical sample harvesting.  An example is the preclinical studies carried 
out by Laurie and colleagues [60].  In this study they looked at the vitreal drug exposure 
in rats.  As this study gave exceptional insight to the vitreal drug exposure, it could not 
be compared to any human studies because of visual damage or tumor dissemination 
risks [65, 67].  To compare dosage among different species, alternative parameters can 
be used and compared.  One parameter for subconjunctival injections is the species! eye 
volume.  This can help estimate the available volume that can be injected.  While in 
principle it is similar to the BSA measurement, this focuses directly on the region of 
interest; however it too has limitations because it fails to account for each biological 
parameter difference.  Nonetheless these challenges provide a framework to learn more 
about clinical drug treatment.   
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As described in the following chapters, my graduate thesis work has addressed 
two specific issues relevant to the assessment and development of preclinical 
approaches for the treatment of retinoblastoma.  First, I have conducted a preclinical 
study looking at the combination of a local and systemic administration of carboplatin 
and topotecan.  I found a local injection increases the drug exposure in the vitreous and 
decrease systemic exposure.  This is an important finding for children with the germline 
mutation.  In addition, an ideal combination of two well-studied board spectrum 
chemotherapy agents, carboplatin in the subconjunctival space and topotecan i.p. has 
shown good tumor response with minimal systemic and local toxicity.   
 
Along with determining the best chemotherapy combination in my preclinical 
model, I have optimized the use of clinical modalities for mice and determined tumor 
progression in various models.  Not only does this non-invasive longitudinal study make 
the preclinical research truly translational, but also gives a sense of retinoblastoma 
growth and progression in various sporadic mouse models.  These finding will lay the 
foundation for future preclinical studies and help define the role of different genes in 
retinoblastoma tumor formation. 
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CHAPTER 2. PHARMACOLOGY* 
 
 
2.1 INTRODUCTION 
 
Patients with retinoblastoma have not fully benefited from advances in drug 
development and methods to deliver chemotherapy locally to the eye, in part, because 
few preclinical models have been developed that faithfully recapitulate the human 
disease.  Preclinical animal models are essential for studying childhood cancers such as 
retinoblastoma, because there are too few patients for large-scale clinical trials [124].  
The recent development of several new rodent models of retinoblastoma has opened the 
door to key advances in the treatment of bilateral retinoblastoma [60, 125] and the 
preservation of vision in children with this debilitating disease. Using an orthotopic 
xenograft model of retinoblastoma, we have previously shown that the combination of 
systemic topotecan and carboplatin is more effective than the current standard of care 
used around the world (e.g., etoposide, vincristine and carboplatin) [60].  Unfortunately, 
the dose-limiting toxicity of each of these drugs is myelosuppression and thus, the 
systemic co-administration of these compounds in patients at therapeutic dosages is 
associated with intolerable toxicities.  
 
Two alternative approaches are available to allow for the co-administration of 
these two highly active agents and yet avoid the side effects associated with their use. 
First, the drugs could be administered at different times during the chemotherapeutic 
schedule with close monitoring of blood counts to ensure that myelosuppression does 
not reach dangerous levels.  The limitation of this approach is that the individual tumor 
cells will only be exposed to a single agent at any given time during chemotherapy.  The 
second approach is to administer one drug locally to the eye to minimize systemic 
exposure so that the second drug could be administered systemically.  The first study to 
demonstrate the feasibility of locally delivered chemotherapy for children with 
retinoblastoma was carried out by Abramson and colleagues who used subconjunctival 
administration of carboplatin (20 mg/eye) [65].  Indeed, retinoblastoma is ideal for local 
delivery of chemotherapy, because the eye is readily accessible and it may be possible 
to achieve high intraocular concentrations with lower systemic exposure.  
 
In this study, we perform a side-by-side comparison of subconjunctival 
carboplatin with systemic topotecan to subconjunctival topotecan with systemic 
carboplatin. Pharmacokinetic experiments were performed to determine if carboplatin or 
topotecan was better suited to subconjunctival injection in our efforts to minimize 
systemic exposure and toxicities.  We also performed toxicity studies and 
pharmacodynamic experiments to help guide future clinical trials using this approach. To 
the best of our knowledge, this is the first comprehensive preclinical study that 
incorporates pharmacokinetics, pharmacodynamics and functional assessment in a 
pediatric cancer model.  
 
 
*  Modified with permission.  Nemeth, K.M., et al., Improved retinoblastoma treatment 
   using subconjunctival carboplatin and systemic topotecan in preclinical models. 
   Cancer, 2010 (in press) [1]. 
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2.2 MATERIAL AND METHODS  
 
 
2.2.1 Retinoblastoma orthotopic xenograft model   
 
Newborn Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) 
received an intravitreal injection of 1,000 Y79-Luc cells as described previously [125].  
After approximately two weeks, the cells expanded and the tumor mass could be 
detected using Xenogen IVIS 200 system and Live Image Software 2.5 after an i.p. 
injection of D-luciferin (Caliper LifeScience, Hopkinton, MA).  The D-luciferin dosage was 
100mg/kg and animals were imaged 30 minutes after the injection. 
 
 
2.2.2 Pharmacokinetic studies   
 
Two-week-old rats were treated with topotecan (TPT; Hycamtin; 
GlaxoSmithKline, research Triangle Park, NC) at a dose of 10mg per eye, carboplatin 
(CBP; Paraplatin; Bristol-Myers Squibb, New York, NY) at a dose of 100mg/eye.  For a 
typical experiment, 18 animals received subconjunctival injections of either topotecan or 
carboplatin in both eyes.  At serial time points (pre, 15 minute, 0.5 minute, 1.5m, 4 and 6 
hour) a cardiac puncture was performed, blood collected and plasma isolated.  Once the 
cardiac puncture was completed, the animals were euthanized by cervical dislocation, 
the eyes were removed and the vitreous and retina were collected and flash frozen. 
 
For topotecan, total topotecan (lactone plus carboxylate) was quantitated by a 
sensitive and specific reversed phase isocratic HPLC.  Calibration curves were 
constructed using appropriate black control matrices.  This method was linear over a 
range of 0.25 to 5000ng/ml, and the lower limit of quantitation was 0.25ng/ml.  For 
carboplatin, total platinum was quantitated by sensitive atomic absorption spectroscopy 
method.  Briefly, plasma and vitreous samples were spiked with 1N nitric acid, vortexed 
and centrifuged at 5000 rpm for 3 min.  Concentrations of total platinum in supernatants 
were quantified using flames atomic absorption spectrometry after diluting the matrix in 
water containing 0.2% (v/v) Triton X-100 and 0.06% (w/v) cesium chloride.  Samples 
(20µl) were injected in duplicate into a Perkin Elmer Analyst 6000 atomic absorption 
spectrometer (Perkein Elmer, Norwal, CT) with Zeeman Background corrections to 
measure platinum content.  Peak area measurements were performed at a wavelength 
of 265.9 nm with a slit width of 0.7 nm.  Total platinum concentrations were determined 
by interpolation on calibration curves constructed form drug-free matrices (plasma or 
vitreous).   
 
An appropriate pharmacokinetic model was fit to the topotecan or carboplatin 
plasma or vitreous concentration-time data using the ADAPT software, version 5.0.0 
(Biomedical Simulations Resource, Los Angeles, CA).  Estimated model parameters 
included the volume of the central compartment (vc), elimination rate constant (ke) and 
when appropriate the inter-compartment rate constants (kcp and kpc).  Systemic 
clearance (CL) was calculated using the model parameters.  The area under the 
topotecan or carboplatin plasma or vitreous concentration-time curve from 0-6 hours 
(AUC 0-6) was calculated using the parameter estimates and the log-linear trapezoidal 
method. 
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For isolation of the different portions of the eye, we have optimized the procedure 
for this method over the past several years with a series of control experiments.  Briefly, 
the eye is removed form the animal with a pair of #3 forceps and it is immediately rinsed 
in an excess of sterile saline (10ml/eye).  Then the eye is dried on sterile cotton pads to 
ensure that any saline on the surface of the eye does not dilute the vitreous sample.  
The eye is then punctured in a dry, sterile 6 cm tissue culture dish with an 18 Ga needle 
and dissected with #5 forceps.  The forceps are sterilized and cleaned between eyes 
and animals and we use a different set of forceps for the dissection than the enucleation.  
We also harvest the eyes with the lowest concentration of drug first (longest time points) 
to minimize the cross concentration from the sample to sample the forceps.  A series of 
experiments by dissecting was never exposed to drug with forceps used for PK studies 
has shown that there is no detectable cross contamination across samples.  The 
vitreous is collected form the dish with a sterile 20-microliter pipette tip and placed in a 
siliconized sterile eppendorf tube.  The retina is then rinsed in 10 ml sterile saline, 
excess saline is removed and it is placed in another sterile siliconized eppendorf tube.  A 
series of experiments that involved mixing of vitreous from an untreated animal with 
vitreous with a treated retina, sclera or lens showed no detectable cross contamination 
with these methods. 
 
 
2.2.3 Tonometer 
 
Intraocular pressure (IOP) of sedated mice was measured with the TonoLab 
Rebound Rodent Tonometer (Tonolab, Espoo, Finland).  Mice were anesthetized using 
isoflurane and measurements were taken at the same time of the day, approximately six 
hours into the light cycle.  The device was held so that the probe was between 1-4mm 
from the cornea of the eye.  Six consecutive measurements were taken and average to 
obtain final value for each eye.  Baseline measurements were taken before 
subconjunctival injections and then at 1, 2 and 7 days after subconjunctival injection. 
 
 
2.2.4 Optomotry 
 
Visual acuity was measured using the OptoMotry System (Cerebral Mechanics, 
Alberta, Canada) as previously described [126].  All tests were carried out in bright light 
conditions to measure cone function.  Visual acuity of the mouse was measured with at 
least two consecutive measurements on independent days 24 hours before and after 
administration of drug.  A second set of measurements was made on 2 consecutive days 
1 week after administration of the drug. 
 
 
2.2.5 Histology 
 
Eyes were fixed in 4% paraformaldehyde overnight at 4°C, dehydrated through 
an alcohol series and washed in xylene.  Eyes were paraffin embedded and sectioned (5 
µm) in the sagittal plane through the optic nerve.  The cornea, ciliary epithelium, retina 
and optic nerves were compared across treated and untreated eyes at 1, 2 and 7 days 
after administration of the subconjunctival injection. 
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2.2.6 Blood counts   
 
To assess the hematopoietic toxicity of topotecan and carboplatin, a standard 
CBC with differential was obtained at the time points specified in the Results section.  
The facial vein was used for blood draws to prevent any disruption of the ocular structure 
that may arise as a result of retro-orbital draws.  Nearly 30µl of blood was collected and 
mixed with 3µl of EDTA.  The samples were processed immediately using the Forcyte 
Machine (Oxford Scientific, Oxford, CT) to count the number of neutrophil, platelets and 
red blood cells.  
 
 
2.3 RESULTS  
 
 
2.3.1 Pharmacokinetics of subconjunctival carboplatin and topotecan 
 
Phase I clinical trials have demonstrated that subconjunctival carboplatin [65] or 
subconjunctival topotecan [67] are well tolerated in retinoblastoma patients as single 
agents.  To determine the extent of intraocular penetration and systemic exposure for 
each drug after subconjunctival administration in our rodent models, we performed a 
series of pharmacokinetic experiments in juvenile rats (2 weeks old) as described 
previously [60].  The topotecan dose was 10 mg/eye with bilateral injections and the 
carboplatin dose was 100 mg/eye with bilateral injections.  Based on the proportional 
volume of the human and rat eyes, these doses were based on those used in Phase I 
trials in children [65, 67] (Table 2-1). 
 
After subconjunctival injection of topotecan or carboplatin, vitreous, plasma and 
retina were harvested and retina were carefully rinsed in saline to remove any drug that 
was in the vitreous of the eye.  The drug concentration was measured in each sample 
across time points.  The AUC values for plasma and vitreous for carboplatin and 
topotecan were calculated from model parameters (Fig. 2-1A,B and Table 2-2). These 
data suggest that both carboplatin and topotecan efficiently penetrate the vitreous after 
subconjunctival injection.  The AUCvitreous/AUCplasma for topotecan was 2.0 and the AUC 
vitreous/plasma for carboplatin was 0.85 suggesting that topotecan penetrated the 
vitreous with slightly greater efficiency than carboplatin. 
 
Next, we evaluated the pharmacokinetics of subconjunctival topotecan and 
carboplatin in tumor bearing juvenile rats to determine if the presence of a rapidly 
growing tumor in the vitreous altered the pharmacokinetic profile for these drugs.  To 
establish tumors, 1,000 Y79-Luc human retinoblastoma cells were injected into the  
vitreous of newborn Sprague Dawley rats [60]  The tumor burden was measured 7 days 
later using the Xenogen imaging system to detect luminescence from the luciferase 
reporter gene in the Y79 cells.  The tumor burden is directly proportional to the 
photons/cm/sec2 detected using the Xenogen imaging system [112].  When the tumor 
burden reached the level of 106 photons/cm/sec2, we performed a pharmacokinetic 
experiment similar to that described above.  The results show that the vitreal penetration 
of carboplatin was similar in eyes with tumor (AUCvitreous/AUCplasma = 1.3) as compared to 
those without tumor (AUCvitreous/AUCplasma = 0.85) (Fig. 2-2A and Table 2-2).  However, 
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Table 2-1. AUC Guided Dose Conversion from Human to Rodent. 
 
Drug Route Human 
dosage 
Human plasma 
AUC 
Rodent 
equivalent 
dose 
Rodent 
AUC 
dose 
Topotecan i.p./ i.v. 2.7 mg/m2 80-120 mg/ml•hr 
 
0.45-.9 mg/kg 0.2 mg/kg 
Topotecan s.c. 2 mg/eye 104 mg/ml•hr 
 
0.01 mg/eye n.a. 
Carboplatin i.p./ i.v. 560 mg/m2 260-430 
mg/ml•hr 
 
180 mg/kg 35 mg/kg 
Carboplatin s.c. 20 mg/eye n.a. 
 
0.1 mg/eye n.a.  
 
Notes: i.p. = intraperitoneal; s.c. = subconjunctival; AUC = area under the curve.   
 
 
 
 
 
 
 
Figure 2-1. Pharmacokinetics of Carboplatin and Topotecan Following 
Subconjunctival Injection in 2-week Old Rats. 
Ocular and systemic pharmacokinetic analysis of carboplatin (100 µg/eye in both eyes) 
(A) and topotecan (10 µg/eye in both eyes) (B). A two-compartment model was used to 
determine the AUC value. µM = micromolar; AUC = area under the curve. 
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Table 2-2. Subconjunctival AUC Values in Tumor and Non-tumor Rats. 
 
  Non-tumor bearing Tumor bearing  
Drug 
(dose) 
Route AUCplasma AUCvitreous Ratio AUCplasma AUCvitreous Ratio 
Topotecan 
(10µg/eye) 
 
s.c. 1.1 µM!h 2.27 µM!h 1.98 1.4 µM!h 8.78 µM!h 6.12 
Carboplatin 
(100µg/eye) 
s.c. 53.6 
µM!h 
53.6 µM!h 0.85 32.2 
µM!h 
40.7 µM!h 1.26 
 
Notes: i.p. = intraperitoneal; s.c. = subconjunctival; AUC = area under the curve. 
 
 
 
 
 
 
 
Figure 2-2. Pharmacokinetics of Carboplatin and Topotecan Following 
Subconjunctival Injection in 2-week Old Tumor Bearing Rats. 
Ocular and systemic pharmacokinetic analysis of carboplatin (100 µg/eye in both eyes) 
(A) and topotecan (10 µg/eye in both eyes) (B).  A two-compartment model was used to 
determine the AUC value. µM = micromolar; AUC = area under the curve. 
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the vitreal penetration for topotecan increases in eyes with tumor (AUCvitreous/AUCplasma = 
6.1) as compared to those lacking any tumor (AUCvitreous/AUCplasma = 2.0) (Fig. 2-2B and 
Table 2-2). For both drugs, the exposure of the vitreous relative to the systemic 
exposure (AUCvitreous/AUCplasma) was greater with subconjunctival injections as compared 
to the intraperitoneal injections (Table 2-3) as described previously [60]. 
 
 
2.3.2 Contralateral eye exposure to carboplatin and topotecan from a subconjunctival 
injection 
 
As mentioned above, subconjunctival injection of topotecan or carboplatin leads 
to greater relative intravitreal exposure in orthotopic xenograft models than systemic 
administration using intraperitoneal injections.  However, there is significant plasma 
exposure to topotecan and carboplatin when the drugs are injected into the 
subconjunctival space.  To measure the exposure of the contralateral eye after a single 
subconjunctival injection of topotecan and carboplatin, we performed a pharmacokinetic 
experiment similar to those described above except only one eye was injected.  At each 
time point we harvested the injected eye and the contralateral eye separately and 
measured the topotecan and carboplatin exposure.  The AUC ratio (vitreous/plasma) 
values in the contralateral eye (Table 2-4) are less than that of the injected eye and are 
similar to those determined after intraperitoneal injections. 
 
 
2.3.3 Comparison of the pharmacodynamics of subconjunctival topotecan to 
subconjunctival carboplatin 
 
To test whether there was a difference in the retinoblastoma tumor response 
using subconjunctival topotecan/systemic carboplatin or subconjunctival 
carboplatin/systemic topotecan, we performed a pharmacodynamic experiment using our 
rat xenograft model.  Y79-Luc cells were injected into the vitreous of newborn Sprague 
Dawley rats and when the tumor burden reached 1x 105 photons/cm/sec2, treatment 
was initiated.  The animals were randomly divided into 3 groups (saline, subconjunctival 
topotecan (10µg/eye)/systemic carboplatin (10mg/kg) and subconjunctival carboplatin 
(100 µg/eye)/systemic topotecan (0.2 mg/kg-daily x 5) (Fig. 2-3A-F). 
 
The systemic exposure (AUC) and schedule of drugs used in this study 
recapitulate those used in clinical trials as closely as possible taking into account 
species-specific toxicity (Appendix B).  In the saline treated group, the tumor burden 
increased by ~100-fold (Fig. 2-3A) and for the treated groups, there was an 
approximately 10-fold reduction in tumor burden compared to the saline injected group 
(Fig. 2-3B,C).  One of the most striking and surprising differences between the two 
treatment groups was the morbidity associated with subconjunctival topotecan and 
systemic carboplatin (Fig. 2-3C).  In this group, none of the animals survived past the 
5th day of chemotherapy.  A representative example of untreated and a treated 
(subconjunctival carboplatin/systemic topotecan) animal with corresponding 
histopathology are shown in Fig. 2-3D-F. 
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Table 2-3. Ocular and Systemic Topotecan and Carboplatin Exposure by 
Intraperitoneal and Subconjunctival Injections. 
 
  Non-tumor bearing Tumor bearing 3 
Drug 
(dose) 
Route AUCplasma AUCvitreous Ratio
2 AUCplasma AUCvitreous Ratio
2 
Topotecan 
(2 mg/kg) 
 
i.p. 2.69 
µM!h1 
1.02 
µM!h1 
0.381 n.a. n.a. n.a. 
Topotecan 
(10µg/eye) 
 
s.c. 1.14 
µM!h 
2.27 µM!h 1.98 1.44 
µM!h 
8.78 µM!h 6.12 
Carboplatin 
(70mg/kg) 
 
i.p. 559 
µM!h1 
330 µM!h1 0.591 n.a. n.a. n.a. 
Carboplatin 
(100µg/eye) 
s.c. 53.6 
µM!h 
53.6 µM!h 0.85 32.2 
µM!h 
40.7 µM!h 1.26 
 
Notes: i.p. = intraperitoneal; s.c. = subconjunctival; AUC = area under the curve. 
1 Values of i.p. AUC ratios were previously published.  Source: Laurie, N.A., et al., 
Topotecan combination chemotherapy in two new rodent models of retinoblastoma. 
Clin Cancer Res, 2005. 11(20): p. 7569-78 [60].  The dose was 2 mg/kg.  
2 The ratio of AUC vitreous/ AUC plasma is used to provide an estimate of the ocular  
exposure to each drug. 
3 For tumor bearing rats, 1,000 Y79-Luc cells were injected into the vitreous at P0  
and then the animals were monitored daily from p7 using Xenogene Ivis 200. 
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Table 2-4. Comparison of Vitreal Exposure of Topotecan and Carboplatin. 
 
                                  Area under the curve ratio (vitreous/plasma) 
Drug Intraperitoneal1 Subconjunctival2 
(injected eye) 
Subconjunctival3 
(contralateral eye) 
Topotecan 0.38 2.0 0.35 
 
Carboplatin 0.59 0.85 0.62 
 
1 Values of i.p. AUC ratios were previously published.  Source: Laurie, N.A., et al., 
Topotecan combination chemotherapy in two new rodent models of retinoblastoma. 
Clin Cancer Res, 2005. 11(20): p. 7569-78 [60].  The dose was 2 mg/kg.  
2 The dose for the subconjunctival injections was 10 µg/eye for topotecan and 100  
µg/eye for carboplatin.  Both were injected. 
3 The dose for the subconjunctival injection was 10 µg/eye for topotecan and 100 µg/eye  
for carboplatin.  The left was injected and the right eye was analyzed in this experiment 
similar to those determined after intrapertioneal injections.  
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Figure 2-3. Pharmacodynamic of Subconjunctival Topotecan with Systemic 
Carboplatin and Subconjunctival Carboplatin with Systemic Topotecan. 
Juvenile rats received (A) saline injections, (B) received subconjunctival carboplatin (100 
mg/eye) and systemic topotecan 0.2 mg/kg daily x 5 by intraperitoneal injection and (C) 
received topotecan (10 mg/eye) by subconjunctival injection and carboplatin (18 mg/kg) 
by intraperitoneal injection.  All data were normalized to the starting tumor burden to 
provide relative growth and response (D-F).  Data for a representative untreated animals 
and an animal treated with subconjunctival carboplatin and systemic topotecan including 
bioluminescence measurements and histopathologic analysis.  Scale bar: 25 µm. N: the 
number of animals. p/sec/cm2: photons per second centimeter square.  
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2.3.4 Analysis of ocular toxicity following subconjunctival topotecan or carboplatin 
 
To test ocular toxicity of subconjunctival administration of either topotecan or 
carboplatin, we used a cohort of 12 C57Bl/6 mice divided into 4 groups (untreated, 
subconjunctival saline (10"l), subconjunctival topotecan (10"g/eye) and subconjunctival 
carboplatin (100"g/eye)) administered to one eye (Fig. 2-4A-C). The eyes were 
examined 1, 3 and 7 days later for signs of inflammation or other periocular side effects 
associated with the injection. There were no visible signs of ocular toxicity associated 
with any of the injections (Fig. 2-4A-C). We also monitored the animals for any signs of 
elevated intraocular pressure using a rodent tonometer and monitored visual acuity 
using the Optomotry system [126].  There was no evidence for changes in intraocular 
pressure or visual acuity for subconjunctival carboplatin or subconjunctival topotecan at 
any of the time points tested. 
 
In a similar experiment, we combined subconjunctival injections with systemic 
administration to determine if there were any ocular toxicity from the exposure of the eye 
structures to both topotecan and carboplatin. Using 3 C57Bl/6 mice per group in 4 
groups, we compared the ocular toxicity, visual acuity and intraocular pressure in 
animals receiving 10"g/eye topotecan with 18 mg/kg carboplatin by intraperitoneal 
injection and 100"g/eye carboplatin with 0.1 mg/kg topotecan. After 1, 3 and 7 days 
there was no difference in ocular appearance, intraocular pressure or visual acuity in any 
of the groups (Fig. 2-5). Histopathological analysis confirmed that there were no obvious  
changes in the retina, ciliary epithelium or cornea of the eyes exposed to subconjunctival 
carboplatin or topotecan (Fig. 2-6). 
 
 
2.3.5 Myelosuppression and dehydration associated with subconjunctival topotecan 
and systemic carboplatin 
 
Having established that there is no significant ocular toxicity associated with 
either subconjunctival carboplatin or topotecan (alone or in combination), we proceeded 
to study systemic toxicity associated with these drugs.  We used 7 P8 rat pups and 
administered 100"g carboplatin to one eye and 0.2 mg/kg topotecan by i.p. 
administration.  According to the schedule of topotecan administration in children with 
retinoblastoma, we proceeded to administer 0.2 mg/kg for the subsequent 4 days to 
mimic a dailyx5 schedule.  Their weight was measured each day for a total of 9 days and 
compared to untreated littermates (Fig. 2-7A).  We could not detect any significant 
weight loss using this treatment protocol.  We also collected blood by facial vein blood 
draw prior to treatment and on the 10 days after treatment to performed a CBC to 
monitor blood counts.  There was no notable reduction in blood counts after treatment in 
this cohort of animals.   
 
Next, we performed a similar experiment with subconjunctival topotecan (10"g) 
and systemic carboplatin (34 mg/kg) based on previous clinical data, AUC guided doses.  
Unfortunately, the rats couldn!t tolerate the combination of topotecan and carboplatin 
using this route (subconjunctival topotecan and systemic carboplatin) and dosage. 
 
In a second experiment, we reduced the carboplatin dose to 10 mg/kg and 3 of 6 
animals survived to day 6 of treatment.  In contrast to the subconjunctival carboplatin 
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Figure 2-4. Analysis of Ocular Effects of Subconjunctival Administration of 
Chemotherapeutics. 
(A) Photos of eyes of C57Bl/6 mice 48 hours after subconjunctival injection of saline 
10µl, 100µg of carboplatin or 10µg of topotecan. (B) Intraocular pressure, we used a 
rodent tonometer before and after administration or subconjunctival carboplatin and 
topotecan.  Each bar represents the mean and standard deviation of 6 measurements 
form 3 independent animals. (C) Visual acuity measurement the optomotry system. 
Visual acuity was measure before and after injection in the groups of three animals per 
treatment group. The contralateral eye was again used as a control.  The data represent 
the mean and standard deviation of the results from the 3 animals in each group and 
topotecan (10 µg/eye in both eyes). c/d = cycles per degree. 
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Figure 2-5. Visual Acuity and Intraocular Pressure Measurements Following 
Combinations Chemotherapy. 
We compared subconjunctival carboplatin with systemic topotecan or subconjunctival 
topotecan with systemic carboplatin in C57Bl/6 mice to determine if there was ocular 
toxicity.  (A,B) Intraocular pressure, measurements were made before and after each 
combination.  Controls were the contralateral eye and a 10µl saline injection to a parallel 
cohort.  Each bar represents the mean and standard deviation of 6 measurements form 
3 independent animals.  There was no statistically significant difference across groups. 
(C,D).  Visual acuity was measured before and after injection in groups of 3 animals per 
treatment (see above) and the contralateral eye was again used as a control.  The data 
represent the mean and standard deviation of the results from the 3 animals in each 
group.  There was no statistically significant difference in the visual acuity across groups.  
IOP = intraocular pressure; mm HG = millimeter mercury; c/d = cycle per degree. 
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Figure 2-6. Histopathological Analysis of Ocular Structures Following 
Subconjunctival Injections of Topotecan or Carboplatin. 
Representative images of H&E stained sections form paraffin blocks of eyes treated with 
subconjunctival saline (A-D), carboplatin (E-H) or topotecan (I-J).  Retina, cornea, iris, 
ciliary epithelium (CE) and optic nerve (ON) are shown.  ONL: outer nuclear layer, INL: 
inner nuclear layer and GCL: ganglion cellular layer.  Scale bar: 25 µm.  
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Figure 2-7. Side Effects of Topotecan and Carboplatin Combination 
Chemotherapy Using Different Routes of Administration. 
(A) The first group received saline injections, the second group received carboplatin 
(100 mg/eye) and topotecan 0.2 mg/kg daily x 5 by intraperitoneal injection and the third 
group received topotecan (10 mg/eye) by subconjunctival injection and carboplatin (10 
mg/kg) by intraperitoneal injection.  Body weight was measured each day for the 
subsequent 9 days.  When the topotecan was administered by subconjunctival injection 
and the carboplatin was administered by i.p. injection and all the animals died by day 6 
of treatment with signs of dehydration.  (B) Blood chemistry for treated and untreated 
juvenile rats. Each bar represents the mean and standard deviation of 2-3 animals. (C) 
Blood cell counts for treated and untreated juvenile rats.  Each bar represents the mean 
and standard deviation of 2-3 animals. Abbreviations: BUN, blood urea nitrogen; WBC, 
white blood cells; NE, neutrophils; RBC, red blood cells; PLT, platelets. 
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and systemic topotecan, this group exhibited signs of profound dehydration including 
significant weight loss, lethargy and tenting of the skin (Fig. 2-7A and data not shown).  
Blood chemistries obtained from the rats that survived to day 6 of treatment 
were normal except for an elevated BUN consistent with chemotherapy-related 
dehydration (Fig. 2-7B).  In addition, blood counts obtained from those same animals 
were consistent with myelosuppression as evidenced by neutropenia and 
thrombocytopenia (Fig. 2-7C).  Taken together, these data show that there is significant 
toxicity associated with subconjunctival topotecan and systemic carboplatin as 
compared to subconjunctival carboplatin and systemic topotecan.  
 
 
2.4 DISCUSSION  
 
Retinoblastoma is unique among pediatric solid tumors because locally delivered 
chemotherapy can be combined with systemically administered chemotherapy to 
optimize intraocular drug exposure while minimizing the side effects associated with 
combination chemotherapy.  In this study, we tested the feasibility, efficacy and toxicity 
associated with combining subconjunctival injection of one drug with systemic 
administration of the other drug.  In this way, we hoped to avoid the side effects of 
intravenous combination chemotherapy while optimizing the vitreal exposure of both 
drugs and the anti-tumor effect.  Using pharmacokinetic and pharmacodynamic 
approaches, we directly compared subconjunctival carboplatin with systemic topotecan  
against subconjunctival topotecan with systemic carboplatin.  The combination of 
subconjunctival carboplatin and systemic topotecan resulted in greater efficacy and 
fewer side effects in the orthotopic xenograft juvenile rodent model.  There were no 
detectable ocular side effects associated with this combination of chemotherapy 
following acute exposure or repeated dosing on a clinically schedule in rodents. Blood 
counts, vision, intraocular pressure, tumor growth and metastasis were closely 
monitored in this longitudinal study to provide the most relevant data in preparation for 
clinical trials using subconjunctival carboplatin combined with systemic topotecan. We 
did not include focal therapy such as laser therapy, which is an integral part of 
retinoblastoma treatment in children.  Therefore, the overall outcome in terms of disease 
progression and saving vision and eyes will likely be much better in patients with 
retinoblastoma receiving subconjunctival carboplatin (20 mg/eye) and systemic 
topotecan starting at 3 mg/m2/day (daily x 5 with a target AUC of 140±20 ng/ml•hr) along 
with focal therapy.  
 
 
2.4.1 Pharmacokinetics 
 
Pharmacokinetic studies are essential in retinoblastoma to determine how much 
drug penetrates the vitreous and to determine the relative plasma exposure for a given 
dosage of chemotherapy.  This is particularly important for the combination of topotecan 
and carboplatin because if the systemic exposure of both drugs is too high it can result in 
dose-limiting myelosuppression.  There were several key findings from our 
pharmacokinetic studies.  First, subconjunctival delivery of topotecan and carboplatin led 
to an increased penetration of the eye as indicated by the vitreal level of drugs achieved. 
Second, the vitreous/plasma AUC ratios indicated that the intraocular penetration of 
topotecan (1.98) was better than carboplatin (0.85) following a subconjunctival injection. 
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Third, the presence of a tumor in the eye led to more efficient penetration of both drugs.  
Fourth, the subconjunctival route of administration led to greater vitreal exposure than 
the systemic route of administration for both drugs.  Fifth, there was detectable exposure 
in the contralateral eye following subconjunctival injection in one eye as a result of the 
uptake of drug into the circulation.  Overall, these data indicate that subconjunctival 
delivery of either drug is feasible for the treatment of retinoblastoma based solely on 
measures of intraocular and systemic exposure.   
 
 
2.4.2 Toxicity 
 
Measurements of visual acuity, intraocular pressure and cytotoxicity by 
histological analysis indicated that there was no detectable ocular toxicity associated 
with subconjunctival injection of either topotecan or carboplatin.  In addition, when 
subconjunctival injection of topotecan or carboplatin was combined with systemic 
exposure of the other drug, we did not observe any changes in ocular physiology or 
histology.  In contrast, chemotherapy-related dehydration and myelosuppression was a 
major challenge in these studies when subconjunctival topotecan was combined with 
systemic carboplatin.  The juvenile rats could not tolerate the dose of 10 "g/eye 
topotecan with 34 mg/kg carboplatin.  Even when the dose of carboplatin was reduced to 
10 mg/kg the animals showed signs of severe dehydration and myelosuppression.  In 
addition, there was some toxicity seen with the dose of 0.5mg/kg of topotecan daily x 5 
with 10 "g/eye of carboplatin.  Once the i.p. dosage was reduced to 0.2 mg/kg of 
topotecan the juvenile rats survived.  In both combinations, this dose de-escalation is 
most likely due to the age of the rats.  Clearly, in terms of side effects, subconjunctival 
carboplatin with systemic topotecan is much better tolerated for the juvenile rodents 
used in our studies.  The other important advantage of the subconjunctival carboplatin 
with systemic topotecan route of administration is the fact that the topotecan can be 
delivered on a daily x 5 schedule.  This provides continued chemotherapeutic exposure 
for several days and this is not possible when using subconjunctival topotecan with 
systemic carboplatin because carboplatin can only be administered on the first day of 
therapy in the humans.   
 
 
2.4.3 Pharmacodynamics 
 
Based on the toxicity data, the preferred route of administration for these two 
drugs is subconjunctival carboplatin and systemic topotecan; however, this is only 
preferred if the tumor response is similar or better as compared to subconjunctival 
topotecan with intraperitoneal carboplatin.  Our pharmacodynamic studies in juvenile rats 
with orthotopic xenografts indicated that the tumor response using subconjunctival 
carboplatin and systemic topotecan was robust and comparable to the other route of 
administration.  It was impossible to monitor the pharmacodynamic response to 
subconjunctival topotecan and systemic carboplatin past 5 days due to the animal 
morbidity.  Therefore, administration of local carboplatin with systemic topotecan is 
preferred for the treatment of retinoblastoma.  
 
The goal of these studies is to directly impact the clinical management of 
retinoblastoma patients by combining topotecan and carboplatin.  More importantly, 
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these data establish the importance of preclinical studies for retinoblastoma and our 
systematic approach can now be used to screen other drug combinations for future 
efforts to preserve vision and save lives for children with retinoblastoma.  
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CHAPTER 3. LONGITUDINAL STUDY  
 
 
3.1 INTRODUCTION  
 
In the late sixties it was first reported that an immunodeficient “nude” mouse 
received a xenograft transplant [127].  With its ease and reproducibility, the xenograph 
flank model has become a major tool in studying human tumors.  In this model the 
mouse!s flank is injected subcutaneously, with either a tumor cell line or a primary 
human tumor [128, 129].  This method allows for the study of the tumor in a three 
dimensional architecture [129] and to study the tumor!s sensitivity to chemotherapeutics 
in vivo providing information that is useful to confirm results obtained in previous in vitro 
studies [128].  In addition, the tumor!s response to treatment can be easily assessed 
with simple caliper measurements [130].  Most importantly these tumors are of human 
origin and response to potential chemotherapeutic is translatable to the clinic.  While the 
flank xenograft model is valuable tool in predicting potential treatments, it has some 
drawbacks.   
 
Along with the advantages of the model, the shortcoming need to be considered 
when designing and interpreting the data generated.  It is important to consider the origin 
of the tumor cells.  If from a tumor biopsy, the model will likely recapitulate the tumor 
closely; whereas, a tumor from a cell line is likely to be less similar to the human 
disease, being more homogenous and undifferentiated largely due to selective pressure 
from in vitro cell culturing [128].  The most basic drawback to the xenograph model is 
that the tumor does not grow naturally.  This tumor is likely composed of a well-
established successful cohort of cancer cells that may have additional genetic lesions or 
chromosomal abnormalities.  Perhaps the most obvious and influential factors are from 
the stromal compartment where the tumor cells are injected.  This includes a different 
vascular system and microenvironment than the original tumor environment, which can 
cause different tumor behavior, such as metastasis [128, 130].  All of these confounds 
will influence pharmacological studies.  More specifically the pharmacological 
parameters, absorption, metabolism, distribution and excretion, will be altered, even if 
the treatment route is similar to the clinic.  Perhaps the most basic and obvious 
drawback of the xenograph model is immunodeficient host, which makes the study to 
treatment impossible.  All of these variables can impact the clinical translation and need 
to be recognized when analyzing the study results.  
 
Due to concerns with the xenograph flank model and advances in mouse genetic 
technology, there has been a shift in model preference.  This advancement has led to 
the generation of mouse models with the genetic mutations thought to be causative in 
human tumors.  Transgenic preclinical models of retinoblastoma have also played an 
important role in identifying and optimizing new therapies for clinical trials.  The first 
successful retinoblastoma model was developed in 2004 [110].  The elimination of RB1 
and p107 genes (Rb lox/- p107-/-) gave researches the potential to easily study in the 
disease in an animal; however, there was only a 60% penetrance and the tumors did not 
recapitulate the human form of the disease.  Since this initial model there have been 
many different mouse models generated by crossing the Rb Lox/- mouse with mice, who 
lack different retinoblastoma family member, such as Rb Lox/Lox ;p130-/- , Rb Lox/Lox ;p107-/-  
and Rb Lox/Lox ;p130-/- ; p107lox/- [131](unpublished data).  Additionally, in 2006 Dr. Michael 
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Dyer!s group reported the generation of a mouse (Rb lox/- p107-/-p53 lox/-) that showed an 
aggressive form of retinoblastoma, which recapitulated the human disease.  This animal 
lacked the p53 tumor suppressor gene and its aggressive nature was later found to be 
due not only to the lack of p53, but also to the over-amplification of MDMX [125].  Each 
one of these models has resulted in successful and breedable models that have the 
potential to develop retinoblastoma.  Even with these tools the translational study of 
retinoblastoma continues to be a challenge.  This is in largely due to the lack of proper 
diagnostic tools or studies to monitor the ocular health in the presence of a tumor.  
 
In the clinic, retinoblastoma is one of the easiest types of cancers to follow using 
ocular health and diagnostic imaging modalities.  These exams confirm the presence of 
retinoblastoma and its response to treatment.  With the development of different rodent 
modalities, similar tests can be used to monitor retinoblastoma progression in mouse 
models and address the preservation of vision after treatment.  These tests include 
measurements of visual acuity and intraocular pressure (IOP), as well as tumor growth 
using retinal camera examination, high-resolution ultrasound and MRI analysis.  
 
Recently reported as the gold standard of visual assessment in mice, optomotry 
is an appropriate measure for the development of baseline and future translational 
studies.  In brief, this modality creates a virtual cylinder with 4 computer monitors that 
surround the mouse standing on a pedestal in the center of the screens.  The screens 
contain moving alternative black and white bars that rotate either clockwise or 
counterclockwise.  The mouse will track these moving bars and the vision of each eyes 
is tested with this involuntary response to the projected image [132].  The IOP was 
measured in a sedated mouse with the tonometer.  This modality quickly assesses the 
pressure difference in the anterior chamber of the eye.  Both preclinical and clinical 
tumors, can be imaged with a retina camera, although this test is sensitive and can be 
conducted in a high throughput manner, it has limitations.  Often peripheral tumors are 
hard to locate and cannot be viewed in a single frame.  Fortunately the ultrasound and 
MRI both have the ability to capture the entire eye in a single view.  The ultrasound can 
detect anterior chamber tumors easily, but it has difficulty imaging the posterior part of 
the eye.  Similar the MRI can image the tumors, but it can also detect posterior tumors 
clearly as well as extraorbital invasion.  Each of these tools has become recently 
available; thus there has not been a published study which carried out a detailed 
characterization or long-term longitudinal study of retinoblastoma tumors form the 
various genetic lesion in the mouse models.  Thus far, it has not been established 
whether one mouse model!s tumor growth better recapitulates the pattern of growth seen 
in human retinoblastomas.  By characterizing each diagnostic modality a better 
understanding of tumor growth will be obtained, allowing us to decode the impact of the 
genetic mutations in the mouse models and compare them to human retinoblastoma.  In 
addition, this understanding strengthens the translational of future preclinical studies to 
early clinical trials. 
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3.2 MATERIAL AND METHODS  
 
 
3.2.1 Mouse strains 
 
C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, 
MA) at approximately six weeks of age.  Chx10-Cre mice were obtained from Dr. Connie 
Cepko (Harvard Medical School, Boston, Massachusetts).  Rb Lox/Lox mice were obtained 
from the National Cancer Institute originally made by Dr. Anton Berns (Netherlands 
Cancer Institute, Amsterdam, Netherlands).  The p107s (p107-/-) and p130-/+ mouse 
strains were obtained from Dr. Tyler Jacks (Massachusetts Institute of Technology, 
Cambridge, Massachusetts).  p53 Lox/Lox mice were from the National Cancer Institute. 
The AIPL-/-  mouse was generated at St. Jude!s Research Hospital by M.A. Dyer [133].  
All animal studies were conducted in accordance with the SJCRH Institutional Animal 
Care and Use committee (IACUC) guidelines. 
 
 
3.2.2 Kowa retina camera 
 
The initial diagnosis and staging of retinoblastoma was visualized with a Kowa 
retinal camera (Tokyo, Japan).  It was fitted to a base to ensure steadiness and a foot 
petal was used to control the shutter. The camera was reconfigured with a 78-diopter 
lens that was mounted 5 cm below the camera and was attached to a rod supported by 
the base. The visual field illuminator was set at level 6, previously shown to produce the 
best results for pigmented mice [134]. All effort was made to minimize reflection. The 
whiskers of the mice were trimmed and the pupils were dilated with 1% Tropicamide 
(atropine) (Bausch & Lomb Incorporated, Tampa, FL).  Housing the mice in a dim cage for 
10 minutes allowed the iris to dilate.  No anesthesia was used to avoid possible 
complication of clouding of the eye.  A conscious rodent was gently held approximately 
3-5 cm under the lens. One hand was used to hold the mouse while the other hand was 
used to pull back the eyelids to avoid lid interference.  Focusing was achieved by 
manually moving the mouse.  In attempt to view the peripheral retina the mouse was 
angled.  Observations were recorded both manual and digitally. 
 
 
3.2.3 Magnetic resonance imaging (MRI) 
 
Tumor-bearing mice were anesthetized using 2-3% isoflurane in O2 for the 
duration of the data acquisition.   They were imaged with a 7-Tesla Bruker Clinscan 
animal MRI scanner (Bruker BioSpin MRI GmbG, Germany) equipped wit Bruker 12s 
gradient (BGS12S) and a four channel phase-array surface coil placed on the mouse!s 
head.   3D Magnetization Prepared Rapid Gradient Echo (MP-RAGE) protocol (Tr 2500 
ms; TE 2.5 ms; T1 1050 ms) was used to produce T1 weighed images (coronal) using a 
matrix of 256 x 146 and FOV of 30 x 20.6 mm.  The slice thickness for the T1 weighted 
images was 0.5 mm.  Initial images were read on a Siemens workstation using Syngo 
MR B15 software (Siemens, Erlangen, Germany) and reviewed with MRIcro software 
(version 1.4).  Three dimensional volume measurements were made using Diacom 
Works (DicomWorks, Lille, France) to calculate eye and tumor ratios. 
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3.2.4 Ultrasonography 
 
Mice were anesthetized with 2-3% isoflurane in O2 (2 liters/ minute), positioned 
laterally and secured on a heated platform.  Although it was occasionally necessary to 
suture open the eyes open (Ethican 5-0 silk) for full globe protraction, taping of the upper 
and lower eyelids was usually sufficient for imaging purposes.  Aquasonic 100 coupling 
gel (Parker Laboratories, Inc, Fairfield, NJ) was applied to the surface of the eye and a 
RMV 708 probe lowered stereotactically to the plane of the eye allowing acquisition of 
images.  The Visual Sonics High Resolution microimaging Vevo 770 system (Visual 
Sonics, Inc., Toronto, Ontario, Canada) was used to record B-mode, 3-Dimensional (3D) 
and power Doppler images.  High-resolution images were acquired (55MHz allowing an 
optimal focal depth of 4.5 mm) in the coronal plane using a field of view of 8x8x10 mm3.  
Using the systems integrated rail and 3D motor, sequential acquisition of high-resolution 
coronal images with a step size of 102 µm allowed for an isotropic resolution of 0.1mm.   
 
 
3.2.5 Tonometer  
 
IOP of sedated mice was measured with the TonoLab Rebound Rodent 
Tonometer (Tonolab, Espoo, Finland).  Mice were anesthetized using 2.5% isoflurane 
and measurements were taken at the same time of the day, approximately six hours into 
the light cycle.  The device was held so that the probe was between 1-4 mm from the 
cornea of the eye.  Six consecutive measurements were taken and averaged to give a 
final value for each eye.   
 
 
3.2.6 Optomotry 
 
Visual acuity was measured using the OptoMotry System (Cerebral Mechanics, 
Alberta, Canada) as previously described [132].  All tests were carried out in bright light 
conditions to measure cone function.  Visual acuity of the mouse was measured with at 
least two consecutive measurements on independent days 24 hours before and after 
administration of drug.  A second set of measurements was made on 2 consecutive days 
1 week after administration of the drug. 
 
 
3.2.7 Histology  
 
Eyes were fixed in 4% paraformaldehyde overnight at 4°C, dehydrated through 
an alcohol series and washed in xylene.  Eyes were paraffin embedded and sectioned (5 
µm) in the sagittal plane through the optic nerve and stained with H&E.  The cornea, 
ciliary epithelium, retina and optic nerves were compared across treated and untreated 
eyes at 1,2 and 7 days after administration of the subconjunctival injection.  
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3.2.8 Statistical calculations 
 
Statistical tests were performed using GraphPad Prism Software for Mac Os X 
version 5.0 (GraphPad software Inc.). A one-way ANOVA and a Tukey!s correction were 
used to compare groups. 
 
 
3.2.9 Calcuation of volume 
 
3.2.9.1 Histology bioquant software 
 
Fixed globes were embedded in paraffin and sliced into 10µm thick sections.  
Every 10th section was stained with H&E (i.e., serial sections with 50µm spacing).  These 
histological sections were viewed and hand traced at 4x magnification using BioQuant 
software program (BIOQUANT Image Analysis Corporation, Nashville TN). Due to the 
various tumor sizes and expansion of the stressed globe the number of images needed 
for a single composite of an eye varied. Three-dimensional digitized histology volumes 
were made by aligning each tracing to a predetermined focal point by the optic nerve 
head.     
 
3.2.9.2 Ultrasound  
 
Volume measurements of the eye and the tumor were determined with VEVO 
software (VisualSonics, Inc., Toronto, Ontario, Canada).  From high-resolution 3D data 
sets, tissue perimeters were hand traced at 0.5 mm intervals and the eye and tumor 
labeled in unique colors to mark the different boundaries.  The Visual Sonics software 
(VisualSonics, Inc., Toronto, Ontario, Canada) was then used then to render and 
calculate calibrated volumes.   The tumor to eye ratio was calculated for each eye. 
 
3.2.9.3 Magnetic resonance imaging MRIcro software 
 
Volume measurement of the eye and tumor were determined by hand tracing 
each slice DicomWorks (DicomWorks, Lille, France).  A traced slice was included if it 
had clear boundaries marking the eye and tumor distinct.  Representative volume was 
determined using the voxel volume that was calculated by multiplying the image 
resolution in each of the three dimensions (x,y,z).  The tumor to eye ratio was calculated 
for each eye. 
 
 
3.3 RESULTS  
 
 
3.3.1 Characterization of imaging and ocular health modalities  
 
3.3.1.1 Characterization and measurement of intraocular pressure (IOP) 
 
In the clinic, the IOP of a retinoblastoma eye can increase as the tumor grows 
into the anterior chamber, pressing against the lens or grows into the choroidal layer 
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[29].  Sustained elevated IOP can lead to blindness due to the compression of the optic 
nerve leading to degeneration of these ganglion cell axons.  Before we could determine 
if retinoblastomas in the mouse models have the same effect as in humans, we needed 
to determine the IOP in wild type C57Bl/6 mice. We conducted a baseline study of IOP in 
four male mice, approximately six weeks of age. To determine the reproducibility of the 
tonometer measurements, as well as variation between day and among animals, IOP 
measurements were taken at the same time of the day for 4 consecutive days.  Each 
measurement was performed in sextuplet and averaged.  We found that there was little 
daily variation in the IOP as well as little variation among animals (Fig. 3-1A,B).  The 
IOP measurements we obtained are similar to the average IOP results previously 
described ranging from 10-20 mmHg [135].  These results were not significantly 
different. 
 
Next we wanted to determine if the loss of RB1 and p107 affected baseline IOP. 
This data was important since all of the mice that have the potential to develop 
retinoblastoma are crossed with the Chx10-Cre; RbLox/Lox; p107-/- mouse, thus lacking 2 
genes.  To answer these questions, young mice were monitored for 5 weeks, 7-8 hours 
into their light cycle and compared wild type animals (Fig. 3-1C).  There was no statically 
difference among these comparisons.   
 
Typically an increase in IOP is due to the disruption of fluid movement in the 
eye!s anterior chamber of the eye.  As mentioned above, retinoblastoma growth in the 
human can affect IOP; therefore, it was necessary to see if the rodent tonometer could 
detect a change in IOP in a mouse model of retinoblastoma.  To look at this in detail, the 
p53 TKO model (Chx10-Cre; RbLox/Lox; p107-/-; p53Lox/Lox) were enrolled and tested at 
approximately 6-8 weeks of age.  A small pilot study of three animals was enrolled and 
each eye was monitored independently. This data showed a sudden increase in IOP of 
18 mmHg (Fig. 3-1D).  Once this value or higher was reached the animals were humanly 
sacrificed. 
 
3.3.1.2 Characterization of optomotry visual acuity system 
 
As stated earlier, tumor location and size that leads to an increase in IOP can 
often lead to a loss of vision.  Prior to determining if vision is affected by tumor growth in 
the preclinical models, the Optomotry System was characterized in our hands, with wild 
type mice (C57Bl/6 male mice) and compared to preexisting reports. Five mice were 
enrolled and their vision was studied for five consecutive days.  As a negative control, a 
short-term study with an acute retinal degeneration mouse (aryl hydrocarbon receptor-
interacting protein-like 1 or Aipl1-/-) was also monitored [136].  This genotype is known to 
have early onset of retinal degeneration and at approximately 8 weeks nearly total loss 
of rods and cones, thus is blind [133].  There was little variation in vision between wild 
type mice and over the multiple day study (Fig. 3-2A-C).  As expected, the Aipl1-/- mouse 
never showed a response.  A potential confound for this modality is that it is heavily 
dependent on the mouse!s behavior and users attention.  To our assurance our values 
were similar to previously published data [132].  
 
Previously it was found that in the absence of the Rb1 protein in a developing 
murine retina, rod photoreceptors fail to develop [137].  In addition, it was reported that 
occasional absence of rods might affect cone survival.  To determine if rod degeneration 
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Figure 3-1. Tonometer Characterization of Wild Type C57Bl/6 and 
Retinoblastoma Mice. 
(A) Each eye of four mice was measured individually with the tonometer to look for 
animal-to-animal variation.  There was no significant difference among animals. (B) Each 
eye was measured individually over four days to assess day-to-day variation.  Solid 
symbols represent the right eye, whereas open symbols represent the left eye.  There 
was no significant difference across days. (C) Three 7D mice were followed over 6 
weeks to determine genotype!s IOP baseline. (D) The IOP of three p53 TKO mice were 
followed over thirteen weeks or until morbid status occurred.  IOP = intraocular pressure; 
mm HG = millimeters of mercury. 
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Figure 3-2. Optomotry Characterization of Wild Type C57Bl/6 Mice and AIPL1 -/- 
Mouse. 
(A) Animal-to-animal variation each eye of four mice was measured individually.  There 
was no significant difference. (B) Day-to-day variation each eye was measured 
individually over four days.  Solid symbol or gray shading represents right eye and open 
symbol or striped shading is left eye. There was no significant difference. (C) 
Confirmation of the AIPL1-/- mouse was blind with optomotry modality. 
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could influence visual acuity in retinoblastoma mouse models, a pilot study where each 
eye was treated as its own subject was carried out in Chx10-Cre;Rb Lox/Lox mice as all 
retinoblastoma mouse models are crossed with this genotype.  The test was run under 
bright light conditions which allowed us to solely measure cone function [138].  In 
comparison to wild type mice visual acuity, (0.370-0.460 cycle per degree), the Chx10-
Cre; Rb -/Lox mice had similar visual acuity measurements (0.340-0.420 cycles/degree).  
This data was not statically significant. Additionally, all retinoblastoma mice are crossed 
with a p107-/- mouse to give the double knockout (DKO) (Chx10-Cre;Rb Lox/Lox; p107-/-).  
Therefore, it was important to determine if the visual acuity was similar to wild type and 
Chx10-Cre; Rb Lox/Lox mice.  This short-term study was conducted and gave similar 
range of visual acuity (0.300-0.480 cycles/degree).  This larger range was due to the 
poor behavior of these particular animals.  In addition, different genotypes of tumor 
prone mice were followed to determine if loss of vision would occur over time (Fig. 3-3A-
F).  A decrease in vision was seen for each of the six different genotypes of 
retinoblastoma. 
 
3.3.1.3 Characterization of the Kowa retina camera 
 
Along with visual health assessment in the clinic, children are sedated and 
imaging of their eye!s posterior chamber is viewed with a retinal camera before and 
during treatment.  This fundus inspection helps physicians document the tumor!s status 
and response after therapy.  Many groups have adapted these clinical cameras for 
rodents, which can also image the posterior chamber and assess associated pathologies 
[134, 139].  To determine if the Kowa retinal camera, adapted with a 78-diopter lens, 
could visualize the posterior chamber in our hands, we viewed a wild type C57Bl/6 
mouse and the mutant Nr2e3-/- mouse. This mouse lacks Nr2e3 gene (nuclear receptor 
subfamily2, group E, member 3), which leads to retinal degeneration at a very young age 
[140].  This genotype was chosen because it has a distinct phenotype, a fundus covered 
in small spots [134].  Our images obtained with the Kowa retinal camera are quite similar 
to previously published images. 
 
To the best of our knowledge there have need been published reports of 
retinoblastoma tumors images with the Kowa retinal camera.  To determine if a tumor 
and tumor growth could be detected we looked at a number of retinoblastoma mouse 
models (Fig. 3-4A-C).  The tumor presence and growth was detected and captured with 
this modality. 
 
3.3.1.4 Characterization and ultrasonic tumor detection 
 
The retina camera is very good at detecting tumors in the posterior chamber, but 
a single frame of the entire retina cannot be generated.  Traditionally, the clinic uses 
ultrasonography to closely characterize the size and vascularization of the tumor.  Since 
it has never been reported before, it was necessary to determine if normal and tumor-
bearing eyes could be successfully imaged.  When compared to clinical B-scans, the 
scans of the rodent!s eye were similar.  As expected the tumor-bearing eye was 
successfully imaged and showed the presence of tumor (Fig. 3-5).  Unfortunately, the 
resolution of the margins at the posterior globe was not very clear.  
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Figure 3-3. Loss in Vision Detected with Optomotry for Each. 
A representation of visual acuity measurements for each genotype.  The following 
genotypes included are (A) RB TKO, (B) p107s, (C) p53 TKO, (D) MDMX tg, (E) 3D and 
(F) 7D mice.  The left eye is represented by a solid square, whereas the right eye is 
represented by an open circle.  c/d = cycles per degree. 
 
 
 
 
 
 
 
Figure 3-4. Kowa Retina Camera Detects Tumor Growth. 
The first image is of a non-tumor eye (A).  The second and third images (B,C) show 
tumor growth in the upper left quadrant.  The two white dots in every photo is lens 
reflection. 
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Figure 3-5. A Representation of an Ultrasound Image of Retinoblastoma Mouse. 
An ultrasound scan and Doppler image showing a tumor filled vitreous of the same 
tumor eye.  The color markings represent blood flow in the tumor. 
 
 
It is well known the vasculature is important in the delivery of chemotherapeutic 
agents.  The additional benefit of ultrasound is the ability to visualize the blood vessels 
with the Power Doppler Imaging Mode.  This allows the microvascularity in and around 
the tumor to be imaged and color mapped (Fig. 3-5).  To test if we were able to detect 
tumor vasculature in retinoblastomas 20 mice were scanned of different genotypes (p53 
triple-knockout (Chx10-Cre; RbLox/Lox; p107-/-; p53Lox/Lox), Rb TKO (Chx10-Cre- RbLox/Lox; 
p107-/-; p130Lox/Lox) and MDMX (Chx10-Cre- RbLox/Lox; p107-/-;MDMXtg).  While the 
vascular system was visible in some mice, it was not present in all tumors; however, the 
absence of vessels in these tumors could not be ruled out because additional methods 
of detection were not conducted and may be considered in future studies.   
 
3.3.1.5 Magnetic resonance imaging of tumor detection in tumor-bearing mice 
 
Often the ultrasound can miss part of the tumor due to calcification and 
absorption of sound waves [141].  To complement the ultrasound approach, an 
anatomical MRI scan was used with a small animal 7T MRI system.  This is the most 
straightforward, noninvasive method to study organs and determine tumor presence.  To 
date, no one has followed tumor progression with MRI in retinoblastoma mice.  This 
noninvasive modality produced two different scans, a longitudinal component (T1) and 
transverse component (T2).  In general the T1 component is more detailed and can be 
used to determine tumor volume.  In comparison to control, C57Bl/6, the tumor-bearing 
eyes showed an increase the presence of tumor in the vitreous over time. 
 
To determine if the progression of rodent ocular tumors could be measured an 
abbreviated longitudinal study in p53 triple knockout mice (TKO) was conducted.  
Animals were enrolled in this study at 7-16 weeks of age and scanned weekly until the 
tumor invaded the anterior chamber, resulting in inevitable ocular rupture.  The scan was 
conducted on three different tumor prone mice and each eye was analyzed 
independently (n=6) (Fig. 3-6A-I).  Each eye and tumor was hand traced and the 
tumor/eye ratio was determined using MRIcro software.  An increase tumor volume was 
detected over time for each eye using MRI. At the same time of weekly MRI scans, the 
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Figure 3-6. Analysis of Tumor Development in Retinoblastoma Mice. 
A longitudinal analysis of retinoblastoma tumor development in TKO p53 mice with 
weekly MRI scans (A,D and G) and intraocular pressure measurements with tonometer 
(C, F and I).  For each scan session volume was calculated for tumor volume and eye 
size.  A ratio between the two was calculated using MRIcro software (B, E and H).  The 
ages of the mice were 7 weeks (A and D) and 16 weeks (G).  For the first and second 
mouse (A) MRI scans were conducted at 7 (A1, D1), 8 (A2, D2), 9 (A3, D3) and 10 
weeks (A4, D4); for third mouse (G) MRI scans were conducted at 18 (G1), 18.5 (G2), 
19 (G3) and 20 weeks (G4).  Weekly tonometer measurements were carried out on the 
three mice starring at 5 to 6 weeks of age. Open circle represents left eye and closed 
circle represents right eye.  mm HG = millimeters of mercury. 
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Figure 3-6 (Continued). 
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IOP was measured for each eye.  As previously discussed, the tonometer is a 
straightforward device to monitor pressure changes in the anterior chamber.  The goal 
was to see if there was a correlation between the extent of endophytic growth and 
increase in IOP.  All eyes studied displayed an increase in IOP when significant tumor 
invasion into the anterior chamber occurred, prior to ocular rupture (Fig. 3-6A-I). 
 
 
3.3.2 A comparative volumetric study with ultrasound, MRI and serial sections    
 
The historical approach to studying pathology and size of tumors has been by the 
invasive histological analyses.  While this time consuming technique has been the 
traditional method for a number of years, we wanted to learn if the software capabilities 
of MRI and ultrasound would be more efficient and comparable.  To answer this 
question, five eyes from different retinoblastoma models were used to compare these 
modern techniques to the standard approach.  There were some differences in eye to 
tumor ratio obtained from the three methods (Table 3-1). This data represents that there 
was good correlation for some of the samples. This is likely due to the difficulty in 
defining the posterior boundaries of the tumors.  An increase in sample number may 
resolve the slight variability seen.   
 
 
3.3.3 A longitudinal study using multiple preclinical modalities and mouse models 
 
To understand the role of different genes in tumor progression and growth and 
their influence on ocular health, eye pressure and vision, six different mouse models 
were compared.  These phenotype studies were carried out with multiple observations 
using the retina camera, tonometer and optomotry modalities.  In general, animals were 
enrolled at an age of 50 ± 15 days.  The majority of the genotypes had 7 to 16 mice.  
Previous established Kaplan Meier morbidity data was used to estimate age of tumor 
development.  If tumors did not develop when 50% of the animals showed morbidity they 
were removed from the longitudinal study.  Each eye was analyzed independently (7D 
had 8 samples, 3D had 15 samples, MDMDX had 8 samples, p107s had 16 samples, 
p53 TKO has 14 samples and Rb TKO had 10 samples).  When tumor presence was 
established by retina camera, the mouse was followed until the eye!s rupture was 
inevitable, then it was humanely sacrificed.  Inevitable rupture status was defined as an 
 
 
Table 3-1. Eye/Tumor Ratios from Three Different Modalities. 
 
Sample Gold standard 
eye/tumor ratio 
MRI eye/tumor 
ratio  
Ultrasound 
eye/tumor ratio  
Eye 1 0.27 0.29 0.65 
Eye 2 0.38 0.23 0.78 
Eye 3 0.13 0.38 0.16 
Eye 4 0.27 0.21 0.43 
Eye 5 0.25 0.21 0.17 
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increase in IOP, inability to view the posterior chamber with retina camera, gross 
detection of tumor, an increase in eye size or poor animal health. 
 
To begin the longitudinal study, a retinal camera was used for a visual inspection 
of the eye!s posterior chamber to determine the date of tumor onset detection for each 
genotype.  Mice were monitored approximately every 2 weeks and followed until tumor 
invaded the anterior chamber and the posterior chamber could no longer be viewed.  
The majority of genotypes developed tumors approximately at 63 ± 10 days (Fig. 3-7). 
 
More specifically, p107s mice developed tumors at 73 ± 3.6 days old, p53 TKO at 
60.3 ± 3.8 days, MDMX at 66 ± 2.3 days old and Rb TKO at 53 ± 2.5 days old.  The time 
of tumor development was similar among p53 TKO, MDMX tg, p107s and RB TKO 
groups which were collectively different to 3D(p < 0.001 to p < 0.05).  Interestingly the 
7D group showed a slight difference of time of onset to all (p < 0.5).  Interestingly, the 7D 
and 3D group did not show a significant difference between each other, 114 ± 11.2 and 
123 ± 16.3 days old. 
 
The next obvious question was to look at morbidity to see if there were similar 
differences among groups.  As previously mentioned, the morbid status was marked by 
the time before, imminent eye rupture based on the loss of vision and/or an increase in 
IOP.  Noticeably the first genotype to reach morbid status was Rb TKO at 80.4 ± 8.3 
days old; whereas 3D and 7D were the last, at 256 ± 28 and 342 ± 9.2 days old, 
respectively.  Interestingly, the three of the genotypes MDMX, p107s and p53 TKO, were 
similar in their moribund ages, 105 ± 12, 112 ± 3 and 112.4 ± 9 days old, respectively 
(Fig. 3-8).  There was no significant difference among theses groups; however there was 
a great difference to these and 7D and 3D genotypes.  Even though the 7D and 3D 
genotypes reached morbid status last, there was a significant difference between them 
(p # 0.01). 
 
From the above data sets, the tumor onset to morbid status or tumor progression 
period was calculated (Fig. 3-9).  Tumor progression time was ranked in the following 
order, from shortest time to the longest, RB TKO (16.8 ± 6 days), MDMX (39 ± 10), 
p107s (39.4 ± 4.3), p53 TKO (47 ± 7.8), 3D (133 ± 22) and 7D (228 ± 15.3). The groups 
with rapid tumor progression (MDMX, p53 TKO and p107s) were very similar to each 
other, except for RB TKO, but very different from 3D and 7D subjects (p < 0.001).  
Additionally the 3D and 7D mice were different from each other (p < 0.001).  These 
calculations of the tumor progression period will be helpful in developing an optimal time 
of treatment for future preclinical studies. 
 
In order to develop a comprehensive preclinical study, the six genotypes! loss of 
vision was followed using optometry.  Interestingly the time of tumor onset did not 
immediately affect the animals! cone vision.  In these cohorts some mice were blind 
upon enrollment, poor trackers or were uncooperative.  Their visual acuity or loss could 
not be assessed and therefore the animals were not used for these optomotry studies.  
Upon enrollment age (50 ± 15 days) each eye was tested for a baseline approximately 2 
± 1 times during one week to obtain a baseline.  Visual acuity was then assessed 
approximately every 3 (±1) weeks.  Typically animals with advanced tumors were  
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Figure 3-7. Comparison of Age of Tumor Onset. 
Tumor detection with retina camera.  The y-axis represents the age in days from birth 
and the y-axis represents each genotype.  Data is expressed as mean ± S.E.M.  See 
text for analyses.  A one-way ANOVA and a Tukey!s correction were used to compare 
groups. d= day; MDMX tg (Chx10-Cre- RbLox/Lox; p107-/-;MDMXtg); p53 TKO (Chx10-Cre; 
RbLox/Lox; p107-/-; p53Lox/Lox); p107s Rb (Chx10-Cre; RbLox/Lox; p107-/-); RB TKO (Chx10-
Cre- RbLox/Lox; p107-/-; p130Lox/Lox);7D (Chx10-Cre- RbLox/Lox; p107-/-); 3D (Chx10-Cre- 
RbLox/Lox; p130-/-). 
 
 
 
 
 
 
 
Figure 3-8. Comparison of Morbid Status among Retinoblastoma Mice. 
Morbid status for the six different genotypes was defined as imminent ocular rupture. A 
one-way ANOVA and a Tukey!s correction were used to compare groups.  d = day; 
MDMX tg (Chx10-Cre- RbLox/Lox; p107-/-;MDMXtg); p53 TKO (Chx10-Cre; RbLox/Lox; p107-/-; 
p53Lox/Lox); p107s Rb (Chx10-Cre; RbLox/Lox; p107-/-); RB TKO (Chx10-Cre- RbLox/Lox; p107-
/-; p130Lox/Lox);7D (Chx10-Cre- RbLox/Lox; p107-/-); 3D (Chx10-Cre- RbLox/Lox; p130-/-). 
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Figure 3-9. Comparison of Tumor Progression Period. 
Age at tumor onset and morbid status were subtracted to determine tumor progression 
period.  Data is expressed as mean ± S.E.M.  See text for analyses.  A one-way ANOVA 
and a Tukey!s correction were used to compare groups.  d = day; MDMX tg (Chx10-Cre- 
RbLox/Lox; p107-/-;MDMXtg); p53 TKO (Chx10-Cre; RbLox/Lox; p107-/-; p53Lox/Lox); p107s Rb 
(Chx10-Cre; RbLox/Lox; p107-/-); RB TKO (Chx10-Cre- RbLox/Lox; p107-/-; p130Lox/Lox);7D 
(Chx10-Cre- RbLox/Lox; p107-/-); 3D (Chx10-Cre- RbLox/Lox; p130-/-). 
 
 
screened near or on the day of euthanasia.  Vision loss was defined as a 50% or greater 
decrease from the baseline measurement.  Eyes were not considered to have a change 
if vision loss was less than 50%.  For the mice that meet the above criteria, the loss of 
vision occurred in more than 40% of eyes for all genotypes, except the 3D group where 
about 30% lost vision.  The age of enrollment where vision was lost was in the following 
order, earliest to latest, Rb TKO (16.5 ± 5.5 days), mdmx (20 ± 1), p53 TKO (34 ± 7), 
p107s (35 ± 11), 7D (51 ± 17) and 3D (168 ± 31.46) (Fig. 3-10).  Again the Rb TKO mice 
had the earliest onset of vision loss and earliest tumor onset (53 ± 2.5 days old); 
whereas 3D mice were the last group to have an effect on vision, in agreement with their 
late age of tumor development (123 ± 16.3 days old).  The vision loss of 3D was 
significantly different to the other groups and some to no difference among the others. 
 
Tumor mass can cause an increase in IOP by pressing on the lens and 
disrupting the anterior fluid (aqueous humor) flow.  Ultimately damage of the optic nerves 
result in blindness.  Upon enrollment of a mouse in the longitudinal study (50 ± 15 days) 
a baseline IOP measurement was taken.  There after, IOP measurements (taken in 
sextuplet) occurred approximately bimonthly.  An increase in IOP was defined as 18 mm 
HG or more.  Unlike loss of visual acuity, an increase in IOP occurred in approximately 
20-40% of eyes in all genotypes, except the 7D genotype, which never showed an 
increase in IOP (Fig. 3-11).  IOP increase was usually detected with a large increase in 
tumor mass and immediately prior to a rupture.  The p53 TKO (23 ± 7 days) and Rb 
TKO30 ± 11 days) genotypes showed the earliest increase in IOP, followed by p107s 
(58 ± 9 days) and MDMX (60 ± 11 days) and finally 3D (176 ± 62 days) (Fig. 3-12). 
 61 
 
 
 
 
Figure 3-10. Comparison of Age of Vision Loss. 
Time (days) for each genotype when vision decrease by at least 50%.  Data is 
expressed as mean ± S.E.M.  See text for analyses.  A one-way ANOVA followed by a 
Tukey!s multiple comparison test.  d = day; MDMX tg (Chx10-Cre- RbLox/Lox; p107-/-; 
MDMXtg); p53 TKO (Chx10-Cre; RbLox/Lox; p107-/-; p53Lox/Lox); p107s Rb (Chx10-Cre; 
RbLox/Lox; p107-/-); RB TKO (Chx10-Cre- RbLox/Lox; p107-/-; p130Lox/Lox);7D (Chx10-Cre- 
RbLox/Lox; p107-/-); 3D (Chx10-Cre- RbLox/Lox; p130-/-). 
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Figure 3-11. Comparison of Percentage of Mice with an Increase in IOP. 
Data is expressed as percentage of total mice studied in each genotype.  An increase in 
IOP was never seen in the 7D genotype. 
 
 
 
 
 
 
 
Figure 3-12. Comparison of Age of Increase in IOP Relative to Tumor Detection. 
Data is expressed as mean ± S.E.M.  See text for analyses.  Data determined by one-
way ANOVA followed by Tukey!s multiple comparison test. 
 63 
As seen with the loss of visual acuity, the eyes from the 3D genotype were the last to 
show an increase in IOP and was the greatest difference.  From these results, the 
tonometer data has shown the growth characteristics vary for each genotype.  In 
addition, these different mouse models of retinoblastoma allow genetic analysis of a 
specific gene!s contributions to tumor susceptibility, progression and resistance. 
 
In the clinic retinoblastoma patients often have ocular nerve damage and loss of 
vision due to tumor invasion of the anterior chamber.  This invasion causes an increase 
in IOP.  In the presence of a tumor the IOP can change and therefore tumor mice were 
followed to see if the tumor could be detected with this tool.  However, prior to detecting 
tumors we characterized this modality with wild type animals and various retinoblastoma 
mice.  The wild type mice showed no difference in day-to-day variability or animal-to 
animal variability.  Since all of the retinoblastoma mice are crossed on the RB Lox/Lox; 
p107-/- background we wanted to determine if this genotype!s baseline was similar to the 
wild type findings.  We found that they both had similar baselines.  When we looked at 
the tonometer!s ability to detect tumors in the p53 TKO group, we found an increase in 
IOP typically when the tumor could be seen upon gross inspection.  In support of this 
conclusion, a pilot p53 TKO MRI study group (see below) also showed an increase in 
IOP when tumor invades anterior chamber.  Based on these studies it also appears that 
the IOP increase occurs quickly and precludes an ocular rupture.  We concluded that 
this modality was not effective at detecting early retinoblastomas.  In future studies this 
modality should be used on a weekly bases for tumor animals.  For early tumor 
progression, other modalities should be relied on more heavily 
 
In the clinic, physicians see a decrease in visual acuity with an increase in IOP.  
Previous studies have shown that the optomotry machine is the standard for visual 
assessment in wild type mice [132].  We confirmed that visual acuity was consistent over 
many daily readings in different wild type mice.  Reports have found that in the absence 
of the Rb1 protein in a developing murine retina, rod photoreceptors fail to develop and 
could affect cone development [137]. When a small cohort of RB Lox/Lox mice was 
monitored we found their cone vision was normal.  Young tumor prone double knockout 
7D mice where followed for multiple days and found to have relatively normal vision.  
This group was important to monitor since all of retinoblastoma mouse models were 
breed on this genetic background.  In addition, some vision loss could in tumor mice 
could be detected in all genotypes.  We concluded that the visual acuity of the tumor-
bearing mice could be followed over time, show accurate measurements and could 
detect tumors sooner than the tonometer.   
 
The most common approached to visualize the posterior chamber of the eye and 
to detect an early tumor in the clinic is a retina camera.  Previous reports have 
developed a reliable procedure to view the fundus posterior chamber in mice with the 
human Kowa camera fitted with a 78 diopter lens [134].  We confirmed our ability to 
detect an abnormal retina using a Nr2e3-/- mouse.  As expected, the mutant had a 
marked phenotype of retinal spots all over the fundus, a phenotype originally described 
by Chang and colleagues [142].  Next, retinoblastoma mouse models were followed over 
several weeks to test the modality!s ability to detect tumor formation.  As expected 
tumors were seen and changes in tumor growth and/or seeding were noted over time.  
This finding assured us of the retinal camera!s comparability to the clinic.  The retina 
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camera is an excellent tool for the tumor onset diagnosis and for following moderately 
sized tumors.   
 
 
3.4 CONCLUSION 
 
 
3.4.1 Modality characterization 
 
 While retinoblastoma has been in the research spotlight for nearly 40 years, 
advancement in clinical treatment has not progressed rapidly.  This is due to 
translational limitations, such as the late development of mouse models and the inability 
to follow tumors in real time with diagnostic tools.  The ability to non-invasively follow 
tumor development in preclinical models amount other fields, including pediatric renal 
tube malignancies, neuroblastoma and prostate cancer, has become the standard 
method in testing new therapies [143-145].  Until recently, similar modalities, tonometer, 
optomotry, retina camera, ultrasound and MRI, were not readily available to monitor 
tumor progression in retinoblastoma mice.  In this study, we characterized the multiple 
modalities using several mouse models of retinoblastoma in a noninvasive manner.  In 
addition, these different mouse models of retinoblastoma allow genetic analysis of a 
specific gene!s contributions to tumor susceptibility, progression and resistance.   
 
 In the clinic retinoblastoma patients often have ocular nerve damage and loss of 
vision due to tumor invasion of the anterior chamber.  This invasion causes an increase 
in IOP.  In the presence of a tumor in IOP can change and therefore tumor mice were 
followed to see if the tumor could be detected with this tool.  However, prior to detecting 
tumors we characterized this modality with wild type animals and various retinoblastoma 
mice.  The wild type mice showed no difference in day-to-day variability or animal-to 
animal variability.  Since all of the retinoblastoma mice are crossed on the RB 
Lox/Lox;p107-/- background we wanted to determine if this genotype!s baseline was 
similar to wild type findings.  We found that they both had similar baselines.  When we 
looked at the tonometer!s ability to detect tumors in the p53 TKO group, we found an 
increase in IOP typically when the tumor could be seen upon gross inspection.  In 
support of this conclusion, a p53  TKO MRI study group (see below) also showed an 
increase in IOP when tumor invades anterior chamber.  Based on these studies it also 
appears that the IOP increase occurs quickly and precludes an ocular future.  We 
concluded that this modality was not effective at detecting early retinoblastomas.  In the 
future studies this modality should be used on a weekly bases for tumor animals.  For 
early tumor progression, other modalities should be relied on more heavily. 
 
 In the clinic, physicians see a decrease in visual acuity with an increase in IOP.  
Previous studies have shown that the optomotry machine is the standard for visual 
assessment in wild type mice [132].  We confirmed that visual acuity was consistent over 
many daily readings in different wild type mice.  Reports have found that in the absence 
of the Rb1 protein in a developing murine retina, rod photoreceptors fail to develop and 
could affect cone development [137].  When a small cohort of RB lox/lox mice was 
monitored we found their cone vision was normal.  Young tumor prone double knockout 
7D mice where followed for multiple days and found to have relatively normal vision.  
This group was important to monitor since all of retinoblastoma mouse models were 
 65 
breed on this genetic background.  In addition, some vision loss could in tumor mice 
could be detected in all genotype.  We concluded that the visual acuity of the tumor-
bearing mice could be followed over time, show accurate measurements and could 
detect tumors sooner than the tonometer. 
 
 The most common approached to visualize the posterior chamber of the eye and 
to detect an early tumor in the clinic is a retina camera. Previous reports have developed 
a reliable procedure to view the fundus posterior chamber in mice with the human Kowa 
camera fitted with a 78 diopter lens [134].  We confirmed our ability to detect an 
abnormal retina using a Nr2e3-/- mouse.  As expected, the mutant had a marked 
phenotype of retinal spot all over the fundus, a phenotype originally described by Chang 
and colleagues.  Next, retinoblastoma mouse models were followed over several weeks 
to test the modality!s ability to detect tumor formation.  As expected tumors were seen 
and changes in tumor growth and/or seeding were noted over time.  This finding assured 
us of the retinal camera!s comparability to the clinic.  The retina camera is an excellent 
tool for the tumor onset diagnosis and for following moderately sized tumors. 
 
Over the past few years a number of animal studies using ultrasound and MRI 
has greatly increased.  For many preclinical models in other fields the ultrasound 
detection is limited by the tumor!s location in the body cavity.  One advantage of the 
retinoblastoma tumor is its accessibility by the ultrasound probe. In general, the average 
wild type inbreed mouse eye is 3.33 mm long and the ultrasound probe can emit waves 
approximately 4.5 mm [146].  Based on these measurements we expected this modality 
to be ideal for retinoblastoma detection.  
 
When we scanned the eyes of tumor animals we found several examples of 
anterior chamber invasion.  This promising data correlated well with the clinical detection 
of tumors using high-frequency ultrasound [147].  Therefore the small rodent ultrasound 
appears to be fairly compatible to the clinic.  Unfortunately, like the clinic the major 
challenge was the precise detection of the tumor boundaries when near the optic nerve 
[148].  Based on the probes penetration depth and the average wild type eye!s length, 
good penetration of the posterior chamber was expected; however, this was not the case 
for the majority of eyes tested.  This could be due to the assumption that eye depth is 
same for all mouse strains, but a more likely reason may be due to the common 
characteristic of calcification and shadowing which is a leading cause of sound eave 
obstruction in retinoblastomas [141].  This is a leading cause to sound wave obstruction 
in retinoblastomas.  Even with these drawbacks, the ultrasound!s single field of view and 
the clear detection of the anterior chamber was beneficial.   
 
One unique asset to this imaging modality is its ability to detect tumor blood flow 
with its Doppler mode.  In the clinic, ultrasound can detect tumor vasculature and can be 
beneficial in the design of a chemotherapy plan.  The small animal ultrasound could 
detect an increase in blood flow in retinoblastoma tumors; however, it was unclear if the 
variability seen was direct characteristic of the tumor or a technical limitation of this 
rodent modality.  One way to resolve this uncertainty would be to use 
immunohistochemical markers specific for vessel detection in serial sections.  An 
additional method would be to use contrasting agents as used in the clinic [143].  To our 
knowledge no study has been completed looking at these agents in the rodent eye.  
Perhaps as technology improves this will be an added benefit in ultrasound imaging.   
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A clear, noninvasive image of a single view of retinoblastomas was more 
challenging than originally expected.  To compliment the pervious imaging modalities, 
the use of the 7T small animal MRI was explored.  As mentioned previously, this 
modality can visualize the orbit, external orbit and the brain [131].  An image more 
detailed than the clinic was expected due to the doubling of tesla, which increases 
resolution.  The anterior and posterior chambers, as well as the external orbital tissue, 
could be easily seen in our retinoblastoma mouse models; however, it was impossible to 
determine if the tumor expanded into the different layers of the eye tissues.  This lack of 
detection could be due to the technologic limitations, such as the tesla strength.  To 
determine if tumor progression could be seen over time a small cohort of retinoblastoma 
mice, p53 TKO, were scanned weekly for several weeks.  When we looked at the 
individual mouse images, tumor growth progression could be seen qualitatively and 
quantitatively, by calculating volumes ratios using MRIcro program.  From this pilot study 
we determine that a progression could be seen and quantified easily with MRI.  
 
Tumor volume and size using diagnostic images are typically measured to 
assess the treatment!s success in the clinic.  High-resolution microimaging ultrasound 
has advanced and made it possible to also measure these characteristics in mouse 
prostate tumors with strong correlation to calculations made by serial sections [144].  
Therefore we wanted to determine if tumor volume measured by ultrasound or MRI were 
comparable to the hand tracing method of volume measurements using histology 
images.  We found that there was correlation between the ultrasound and hand trace, 
but even less with the ultrasound, which is likely due to the limited number of serial 
sections tumor!s data collected by MRI.  Future studies should include a smaller step 
size for MRI data collection, however due to the poor animals! health this may not be 
possible because it will increase the time of sedation.   
 
This variation could be a result of many different factors. First, the eye and tumor 
tissue contain a different level of hydration in vivo and ex vivo.  In addition the 
histological process often involves several dehydration steps that could alter the volume 
of the eye when compared to in vivo images.  This had been commonly seen by 
researchers who compared ultrasound volume measurements of the kidney to 
histological sections [145].  Again, one would expect the ratio to correct these 
differences, but it is important to consider that the tissue shrinkage for the eye could be 
different for tumor tissue compared to normal tissue.  Second, comparison between ex 
vivo imaging, MRI and ultrasound was limited by the definition of clear defined 
boundaries.  This is particular true for the ultrasound where tumor shadowing is 
common.  Third the MRI is known to be the highest soft tissue resolution when 
compared to ultrasound. After all of these perimeters are taken in consideration, it is not 
surprising that there is some variation between modalities.   
 
Until recently the retinoblastoma field has had translational limitations, such as 
the inability to follow tumors in real time with diagnostic tools.  In this study, we 
characterized the multiple modalities using several mouse model of retinoblastoma in a 
noninvasive manner.  While the tonometer is a straightforward tool, it was found to only 
detect tumors toward prior to ocular rupture.  In addition it did not detect tumors if they 
did not invaded the anterior chamber.  Even though the optomotry is heavily dependant 
on mouse behavior, we found it to provided sound measurements and was useful in 
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showing the tumor!s progression on vision loss.  The retina camera!s detection of early 
tumor mass was found to be highly superior to the previous modalities.  The other 
imaging tools, MRI and US, strength was in imaging the tumor and eye in one field of 
view.  The ultrasound allowed good imaging of the anterior chamber. In addition it could 
detect blood flow in some of the tumors.  Tumors could be detected much sooner using 
MRI.  We concluded that MRI shows tumor progression over time, measure volume, but 
also predicts tumor presence prior to tumor detection by tonometer.  Finally, the 
comparison of MRI and US volume data sets to histological hand tracing data correlated 
better with the MRI than the US.   
 
 
3.4.2 Longitudinal study 
 
Tumor onset was identified with the retina camera, which provided the earliest 
detection.  Observation of all six genotypes of retinoblastoma mouse models concluded 
that the age of tumor onset was similar for MDMX, p53 TKO, Rb TKO and p107; 
however, tumor onset was delayed in the two double knockout groups, 3D and 7D.  
Similar results were found for the age of morbidity.  Triple knockout mice were younger 
at the time of morbidity status (80-100 days) than the 3D and 7D double knockout 
(morbid status > 200 days old).  It is important to note that there was difference between 
these double knockout groups with 7D mice being the last to die.  It is also important to 
note that there is some variability with these two genotypes.  This could suggest 
heterogeneity for mice that have only two genes deleted perhaps due to genomic 
instability.  Logically tumor progression period followed suit to this pattern and in 
particular we found that the Rb TKO had the shortest progression period.  This suggests 
insult to all three Rb family members greatly increases tumor progression; thus 
reinforcing the common held belief that an increase in the genomic instability leads to an 
aggressive cancer. 
 
 In addition, vision loss was monitored throughout the animal!s life span.  As 
previously mentioned, vision loss was defined as a loss of at least 50% the individual 
baseline for each eye.  Of the six genotypes, 40% of all enrolled eyes have a vision loss, 
except 3D group.  This did not include eyes that were blind at the beginning.  It is 
important to note that the blind eyes were not specific to one particular genotype.  This 
blindness could be due to small genetic lesions that could not have been detected with 
retina camera until they were full-blown tumors.  It is also important to note that animals 
that did not have a 50% reduction in visual acuity were not considered to have vision 
loss.  This could be due to the fact that the mouse!s eye does not have a fovea, a cluster 
of cone cells, therefore a degrees of vision may still be possible based on tumor 
placement.  Perhaps more important to note is that the measurements were done every 
three weeks.  While it would be ideal to measure visual acuity more often, the time 
constrains and manpower made this impossible for the number of enrolled animals.   
 
Typically it is seen that the intraocular pressure increases when the tumor mass 
invades the anterior chamber and presses on the lens or a small tumor seed blocks then 
flow of fluid drainage.  An increase in IOP was defined at 20 ± 2 mm HG. We found that 
20-40% of eyes had an increase in IOP from all genotypes, except the 7D groups.  This 
was expected from previous studies, which showed no anterior invasion with this model 
[110].  Again the triple knockout mice show an increase in IOP the earliest.  
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Triple knockout mice were younger at the time of morbidity status and the tumors 
were more aggressive than the 3D and 7D double knockouts. Of the double knockouts 
7D was the least aggressive than the 3D and 7D double knockout. Of the double 
knockouts 7D was the least aggressive. We found the most aggressive genotype to be 
Rb TKO.  Its short progression period suggested that insult to all three Rb family 
members greatly increases tumor progression.  Of the six genotypes, 40% of all enrolled 
eyes had a vision loss (50% decrease form baseline), except for the 3D group.  This 
could be due to the fact the mouse!s eye does not have a fovea and some vision could 
still be possible based on tumor placement.  However more frequent monitoring, other 
than every three weeks, may improve this percentage.  Additionally a small portion of 
eyes had an increase in IOP in all genotypes, except the 7D group.  To date in the clinic 
there is little evidence that relates the retinoblastoma tumors; phenotypes to related to 
specific gene mutation.  As more human enucleated tumors are studies, insight will be 
gained and further therapeutic can be designed based on preclinical studies.   
 
By using the above modalities in this collective we have shown that similar 
clinical tests could be used to characterized and monitor tumor progression in models of 
retinoblastoma in mice.  We found all the five of the modalities to fully understand the 
picture of tumor progression and its growth pattern.  This is the first time that any of 
these tools have been used in the characterization of retinoblastoma tumors.  Along with 
gene array studies of the tumors in the retinoblastoma models these tools could give a 
comprehensive picture of specific gene involvement in tumor progression and 
phenotype.  
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CHAPTER 4. DISCUSSION AND FUTURE DIRECTIONS 
 
 
4.1 PHARMACOKINETIC STUDIES  
 
The administration of carboplatin and topotecan, as single agents, has been 
successfully tolerated in the retinoblastoma pediatric population [65, 67]; however, the 
long-term success rate for tumor treatment with the single agent, carboplatin, has not 
been promising.  Therefore additional therapy or therapeutic agents are needed.  To 
explore different drug combinations and the effects of a subconjunctival injection in our 
preclinical rodent model, we performed multiple pharmacokinetic and pharmacodynamic 
experiments in juvenile rats.  From these studies we found that there was greater drug 
exposure to the vitreous with a subconjunctival injection.  The subconjunctival data 
suggested there was an increase drug exposure to the vitreous in the presence of the 
tumor.   
 
This finding is likely due to the physiological changes in the eye, such as 
vasculature, disruption of the blood-retinal-barrier, the pressure dynamics or the amount 
of vitreous present.  Increase in vessels could affect the drug concentration either by an 
increase in concentration or a decrease in concentration.  Our data shows an increase in 
drug concentration.  Ultimately it is essential to determine if there are indeed more 
vessels.  This could be done with immunohistochemical analyses on dissected eyes of 
tumor and non-tumor rats [149].  Alternatively the ultrasound Doppler function could 
identify an increase in vascular presence in a rat eye.  Additionally, fluroescein 
angiography could be used to image vessels and compare tumor and non-tumor eyes. If 
these methods show an increase in vascular drug concentration, it could be affected 
three different ways. First, more vessels could result in an increase of drug delivered to 
the eye, however this is unlikely since tumor vascular systems are often inefficient.  
Second, the increase in vessels could move the drugs into the systemic circulatory 
system more rapidly.  From our data this appears not to be the case since both 
carboplatin and topotecan pharmacokinetic experiments in tumor animals showed an 
increase drug in the vitreous.  Lastly, the increase in vessels, which are likely to be leaky 
and disorganized, could prevent the drug from leaving the eye.  An increase in new, and 
perhaps poorly formed, vessels would support the conclusion of the difference in drug 
concentrations.   
 
Alternatively the increased vessels could have a greater vascular permeability or 
leakiness could result in an increase the concentration.  Recently there have been 
reports suggesting permeability could increase the concentration of molecules [149].  An 
indirect way to answer this question is to do a pharmacokinetic study and compare, 
intravenous delivery of drugs to the subconjunctival studies in tumor bearing rats.  If an 
increase in drug exposure to the vitreous is seen, as in subconjunctival injections, it is 
likely that the increased permeability is the result.  However, if this pharmacokinetic 
study does not show an increase in drug exposure this could suggest that the vessels 
are not leaky. 
 
Additionally the tumor could affect protective barriers of the eye, such as the 
blood-retina-barrier either by the tumor release of growth factors or actual growth into it.  
Tumors release a number of growth factors, such as VEGF, to be advantageous to their 
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survival.  The blood-brain-barrier is often compared to the retina-brain-barrier.  Previous 
reports have suggested that the VEGF disrupts the brain!s barrier in the rat by increasing 
the permeability to drugs [150].  Since it is similar to blood-retina-barrier, this could also 
affect the drug exposure to the eye.  To explore this further, antibody markers could be 
used to detect the growth factor in the eye!s barrier.  On the other hand, the actual 
growth of the tumor into the barrier could affect the tissue integrity and thus the 
protection.  Assessment of tight junction proteins would give some insight to this idea.  In 
addition, histological analyses and electron microscopy could give a gross idea of the 
potential changes.  If there were disruptions in the barrier we would expect the layers to 
be non-homogenous. 
 
Alternatively the internal or external pressure dynamics of the tumor or the 
injection could affect the drug exposure to the vitreous.  Olsen and colleagues suggested 
an increase in IOP by decreasing the sclera-choroid-retina permeability [151].  Pressure 
gradients are greater in the presence of a tumor, which would result in a decrease the 
transscleral diffusion; however an increase in drug concentration was seen in our tumor 
modal.  On the other hand, the external pressure from the subconjunctival injection could 
be the cause. If this were true the non-tumor bearing would have a higher drug 
concentration than tumor bearing rats.  This is contrary to our data findings.  Additionally 
the anterior pressure change could affect the clearance of the drug from the eye.  This 
pathway is thought to be one of the potential routes of drug clearance.  Finally, more 
simply, pressure dynamics could indirectly affect the cellular junctions of the barriers, 
leading to less selective barriers and increasing the drug concentration in the tumor rats. 
 
The final idea could be due to the vitreous volume.  There is less vitreous in the 
tumor eye and therefore the drug is less diluted, causing an increase in concentration.  
One simple way to determine if this explanation is correct, is to measure the vitreous 
fluid both the tumor and non-tumor bearing animals.  If there is less vitreous in the tumor 
eyes this may be the cause of the data increase in drug concentration. 
 
Additionally we looked at the drug exposure to the contralateral untreated eye 
with pharmacokinetic experiments.  We found the untreated eyes were exposed to the 
drugs, but at a lower concentration than the treated eye.  We suggested the contralateral 
exposure was due to the uptake of drug by the systemic circulation. This conclusion was 
supported by untreated eye!s AUC ratio of vitreous/plasma was similar to previous 
systemic pharmacokinetic studies [60]. To confirm that the contralateral eye is exposed 
by the system an additional postmortem pharmacokinetic experiment could be carried 
out as Carcaboso and colleagues [152].  Rats could be sacrificed just prior to the 
subconjunctival injection and samples would we harvested a couple hours after 
administration [152].  If the contralateral eye exposed by the systemic circulation, we 
would expect the postmortem untreated eye to be drug free. 
 
Additionally, our data suggests the treated eye has higher drug concentration 
than the untreated eye, suggesting a transscleral mechanism.  Two observations 
support this idea.  One, the vitreal AUC ratios are higher with the treated compared to 
untreated eyes.  Two, the plasma AUC values of subconjunctival injections was less 
than the intravenous injections [60].  However, further exploration needs to be carried 
out to learn about the drug transport with subconjunctival injections of topotecan and 
carboplatin.  More conclusive experiments would include an experiment where the 
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choroid vasculature is disrupted with freezing or heating the vessels.  This would allow 
us to isolate the subconjunctival mechanisms.  Additionally, a window administration of 
the drug in the subconjunctival space would allow the study of the choroid vascular 
influence. 
 
Lastly, we found the vitreous was exposed to a greater concentration of 
carboplatin and topotecan in the presence of a tumor.  Previous intravenous 
pharmacokinetic experiments with carboplatin and topotecan were only studied in non-
tumor barrier animals [60].  To better recapitulate the pharmacokinetics in a 
retinoblastoma model with intravenous injection, it would be of interest to determine if 
vitreal concentration also increased in the presence of a tumor.  Based on our current 
studies and clinical reports, we would expect a tumor to also increase the vitreal drug 
exposure with a intravenous injection [153]. 
 
 
4.2 ALTERNATIVE RAT MODELS FOR PHARMACODYNAMIC STUDIES  
 
The understanding of a drug!s pharmacokinetic properties leads to the 
comprehensive understanding of a drug when pharmacodynamic experiments are also 
carried out.  The previous tumor response studies were carried out in our orthotropic rat 
xenograft model.  We found tumor stability and reduction occurred in animals that were 
treated with an AUC guided dose.  One limitation of this experiment was the length of the 
study.  In these studies, rats developed detectable tumors quickly.  This rapid increase in 
tumor mass is likely a result of the 33 hour doubling time of the Y79 cells [154].  After 
tumor detection rats could only be followed for 7-10 days before ocular rupture of 
untreated animals was inevitable or the limit of detection was reached with the Xenogen 
software.  The use of an alterative retinoblastoma cell line, with a slower doubling time, 
could be engineered with the luciferane report gene.  The well-characterized 
retinoblastoma Weri cell line is an ideal choice for two reasons.  First, the original 
characterization found its doubling time to be approximately 4 days which would allow 
the study to be carried out for a longer period of time [154].  Second, the line was 
recently discovered to have the common genetic lesion, an over application of MDMX, in 
the p53 pathway [125].  Thus using WERI cells would give a better understanding of how 
retinoblastomas respond to chemotherapeutics and allow the potential of a long-term 
study so the schedule of drug delivery could also be investigated.  
 
 
4.3 PRECLINICAL STUDIES AND CONSIDERATIONS  
 
 
4.3.1 Preclinical studies 
 
The major challenge in developing new protocols for pediatric cancers is the 
small patient population.  The use of preclinical rodent models can accelerate the 
development of new therapies and combinations.  Prior to conducting a study there are 
many model considerations that need to be addressed.  The tumor needs to have the 
same genetic lesions as found in the human disease, the same tumor phenotype 
therapeutic response used in humans, time to evaluate the therapy, an endpoint of study 
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and a way to monitor the tumor response [155].  In meeting all of these conditions a 
proper noninvasive longitudinal preclinical study can have great predicative strength.  
 
 With these considerations, the present extensive pharmacological studies in the 
rat, proper calculations for the drug dose and characterization of multiple modalities were 
used to carry out a preclinical study in two of our mouse models.  Enrolled mice received 
the drug combination of a subconjunctival injection of carboplatin and an i.p. injection of 
topotecan (daily x 5) on a clinical schedule (0.7 mg/kg and 0.1 mg/kg for five days).  
After the six rounds of therapy, similar to the clinic, it was found that thirteen of the eyes 
had either partial to full response or stable disease. Surprisingly the use of only two 
agents and no focal therapies showed promising results. Previous studies in the clinic 
have shown that focal therapy can help in tumor response.  Even though focal therapy 
was not used in the current preclinical mouse study, it may provide an added benefit.  
Since our results predict good response in the rat and mouse model, the focal treatment 
may be a good alternative to the three-drug protocol with focal therapies currently used 
in the clinic.  This would lessen systemic exposure, which would be significantly 
beneficial to children with germline mutations. 
 
An additional preclinical study with the added focal therapy could confirm this 
proposal, which would likely expedite the translation time to the clinic. Other preclinical 
studies with retinoblastoma mouse models have used focal therapies, such as EBRT 
and cryotherapy, and found them to disrupt the blood-ocular barrier, increasing drug 
delivery [64, 118, 156].  Ideally, the use of cryotherapy is more attractive than EBRT due 
to the risks to patients with germline mutations.  From these studies it is likely that the 
systemic delivery will be enhanced greater than the subconjunctival delivery [64, 157].  
This would allow a better penetration of topotecan (daily x 5) and may increase the 
response seen in the preclinical mouse study. To date there have been no reports of two 
chemotherapy drugs and focal therapy delivery in preclinical retinoblastoma studies and 
therefore it is of interest to explore this combination. 
 
 
4.3.2 Preclinical considerations 
 
Organ and animal development is important to fully understand because it affects 
the pharmacokinetics of a drug.  Surprisingly this is often overlooked in preclinical and 
clinical trials.  Typically the clinic has treated children as small adults with dose levels 
adjusted only based on body weight or surface area [158].  This approach fails to 
recognize the different developmental stages and can be lead to toxicity.  Many species, 
including humans, have significant postnatal development, organogenesis, increase in 
plasma protein concentration and drug transporter protein development [155].  These 
changes are important to consider for each pharmacokinetic stage: absorption, 
distribution, metabolism and elimination (ADME). 
 
The toxic effects of drugs can occur at any one of the four above 
pharmacokinetic phases.  As previously mentioned in our study group, rats which 
received carboplatin i.p. and topotecan subconjunctival experienced toxicity after a few 
days.  Since death was not immediate the toxicity is likely due to the drug!s elimination.  
Carboplatin!s primary clearance organ is the kidney.  As in human newborns, there is 
significant nephrogenesis postnatally in the rat [159].  To determine if the kidney was the 
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culprit for carboplatin!s toxicity different perimeters, such as the glomerular filtration rate, 
gross inspection with H and E staining and expression drug transporters could be 
measured.  The filtration rate is the traditional method to measure renal and evaluate 
maturation.  Interestingly a comprehensive study of kidney development in rats found its 
maturation was completed at eight weeks of age [160].  Today exogenous markers, such 
as creatinine, in the blood or urine are measured over a period of time [159].  Given this 
previous study and our chemistry results in our rats, young than 8 weeks of age, it is 
likely that they did not have necessary filtration rate, which could have affected the 
animals! clearance and overall exposure to the drug. 
 
However, it is more important to look at the to the developmental changes 
affecting the glomerular filtration rate closer, such as the ontogeny of drug transporters.  
They play a critical role in kidney function or transport.  In general, the number of 
transporters increases absorption or elimination of a xenobiotic.  In brief, the renal 
transport takes place in the tubules where different transporters are located on the 
basolateral membrane and the apical sides.  Xenobiotics are absorbed from the blood on 
the basolateral side and either removed by the urine or effluxed back into the body [161].  
Each drug is a substrate for specific transporters. The transporters for carboplatin are 
multidrug resistance protein 2, copper transporter receptor 1 and organic cation 
transporter 1: whereas, the topotecan is a substrate for p-glycoproteins, multidrug 
resistance-protein 1 and breast cancer resistance protein [162, 163].  Typically when the 
blood with carboplatin passes the basolateral side of renal tubules, it is primarily 
absorbed by the organic cation transport 1 [159].  Interestingly the developing rat kidney 
does not have a high expression of organic cation transporter mRNA doesn!t fully mature 
until six weeks of age [164].  Decreased expression of organic cation transporter 1 could 
result in a slow elimination of the drug and thus increase exposure of carboplatin.  The 
other transporters, multidrug resistance protein 2 and copper transporter, are also 
expressed at levels that are greater than adult and may, theoretically, compensate for 
the lack of organic transporter 1 elimination [158].  In addition, it is necessary to consider 
the transporters for topotecan, since both drugs are given at the same time. Previous 
publications have found that mRNA expression of two of three transporters (multidrug 
resistance protein 1 and breast cancer resistance protein) in the kidney are greater as 
an adult than at birth; however, previous reports have suggested that p-glycoprotein 
reach full mature levels at approximately two weeks of age [158].  While these finding 
help guide us to the cause of toxicity, all of these studies only measured the mRNA 
levels and not protein expression. Therefore it would be necessary to measure protein 
expression of the various transporters in our model!s kidney to fully understand the 
pharmacokinetic properties of our model. 
 
An additional developmental factor that could affect pharmacokinetics is the 
plasma protein and albumin concentrations, which both affect the bioavailability.  
Typically a circulating drug has two different states, bound and unbound.  Unbound drug 
is the amount of drug that is active and available to carry out its function; whereas, the 
bound drug is unavailable to be active because it is bound to circulating proteins.  Each 
drug has a different affinity for the plasma proteins, which can affect their available 
concentration.  Zwart and colleagues looked at these levels in rats younger than six 
weeks and found that they are nearly half that of an adult level [158].  While this is an 
interesting developmental parameter to consider it is unlikely that this is the cause of the 
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toxicity we observed.  Both carboplatin and topotecan have a low affinity for plasma 
proteins and therefore this development would not be an influencing factor.  
 
 
4.4 DIAGNOSTIC APPROACHES  
 
Characterization of the five modalities, tonometer, optomotry, retina camera, 
ultrasound and MRI, strengthened our tumor progression studies; however, we were 
surprised by their limitations.  In the clinic, IOP changes are used to monitor tumor 
progression; however, with the rodent tonometer, early tumor detection was not seen, as 
seen in a comparison of tumor development using MRI and tonometer.  Additional 
longitudinal studies of tumor progression in various genotypes also did not show a 
gradual increase in IOP.  This difference seen between the human and rodent 
indentation tonometer system could be a result of species difference in eye pressure and 
anterior fluid regulation.  Thus our data suggests it is not a good tool to measure the 
progression of retinoblastomas.  Traditionally the alternative method to measure IOP is 
with cannulation; however, this is not ideal for mice with retinoblastoma because of a 
microneedle.  This could lead to tumor dissemination [165]. Therefore, we conclude that 
the tonometer may a good supportive tool for late stage tumor anterior invasion. 
 
Even though optomotry did showed a more gradual decrease in vision with tumor 
progression, this modality strongly depends on the behavior of mice and limited to a four 
hour testing time.  These restrictions led to a three-week schedule of visual assessment.  
This modality may have shown more heterogeneity between retinoblastoma genotypes if 
the animals could have been measured more frequently.  We defined vision loss as a 
50% decrease from the baseline vision.  Interestingly not all of the mice showed 
reduction in vision.  This may have been due to the frequency of monitoring, but more 
likely to the tumor!s location in the eye or the lack of anterior invasion not causing severe 
nerve damage.  It would be ideal to conduct a longitudinal study with visual assessment 
with imaging, such as ultrasound and MRI. 
 
Of the modalities, the retina camera detected tumors the earliest and was used to 
define tumor onset for each genotype (see below).  The noninvasive technique also had 
limitations.  From our data, tumors were detected in 3D and 7D genotypes at the same 
time, approximately at sixteen weeks of age; however previous histological analysis 
studies have shown genetic lesions beginning as early as two weeks in the 7D genotype 
[110].  Similarly, we found the p53 TKO genotype!s tumor onset to be around nine weeks 
of age, whereas earlier histological studies found the tumors to be present as early as 
six weeks of age [4].  Further comparison of the two methods with the additional 
genotypes would give a clear understanding of this modality!s limits.  Nonetheless, retina 
camera!s tumor detection is noninvasive and therefore ideal for preclinical longitudinal 
studies. 
 
Additionally volume comparison studies between ultrasound, MRI and hand-trace 
BioQuant were conducted to determine if the noninvasive methods were comparable to 
the traditional hand tracing of serial sectioning.  We found some correlation between the 
eye tumor ratios of the three ways.  The difference could be due to a couple of factors.  
First, the MRI scans consisted of a lower density of slices.  The majority of the scans, 
that had clear tumor and eye margins, were only about 3-5 image slices for each animal.  
 75 
Second, the MRI images are based off of the proton environment, not absolute tissue 
density like the ultrasound modality.  Perhaps, a longer scan session for MRI data 
acquisition is likely to increase the number of slices thus improving the tumor volume 
measurements.  In addition, further exploration with enhancing dyes for both ultrasound 
and MRI would provide clear tumor/ eye boundaries and thus lead to confident 
distinctions would be beneficial in that they could improve tumor detection parameters.   
 
 
4.5 LONGITUDINAL STUDY OF TUMOR PROGRESSION  
 
The different tumor phenotypes seen in the six genotypes were likely to be a 
result of the combination of the different deleted genes.  The retinoblastoma gene family 
is unique in that it has different temporal expression levels and roles, either redundant or 
compensatory.  Previous developmental data has shown that p107 can compensate for 
the loss of RB [166].  Interestingly this compensation is only possible if both copies of 
the p107 gene are intact.  In addition, the p130 protein provides additional protection 
from tumors in the postnatal developing mouse eye.  In the same study, Donovan and 
colleagues found that p130 function is redundant to that of RB.  To get a better 
understanding of how the loss of different genes could affect the tumor phenotypes, a 
longitudinal study with six different retinoblastoma genotypes was conducted.   
 
In our current study, we looked at tumor onset, progression and morbidity to get 
an understanding of potential roles of the various deleted genes in the phenotypes of 
retinoblastoma.  These differences are likely due to the different combination of deleted 
genes, creating genetic instability, uncontrolled cell growth leading to potential tumors.  It 
is well known that a cell needs at least two genetic hits to reach this state, however with 
more mutations the cells, generally, becomes more instable.  Given this, it is not 
surprising that the double knockout mice, 7D and 3D, had the latest age of tumor onset.  
And as expected the mice with the greater number of gene deletions took less time to 
develop tumors (RB TKO, p53 TKO, p107s and MDMXtg).  Interestingly, the 7D and 3D 
groups developed tumors the around the same time, but time it took for tumors to 
progress and mice reach morbid status was different.  Tumors in the 3D mice 
progressed faster, thus leading to a younger morbid age than the other double knockout 
group.  In the 3D group p107 compensated for RB1 loss, whereas the late detection of 
the 7D tumors is likely due to the redundant nature of p130 for RB1.  As for the other 
genotypes, p53 TKO, p107s and MDMXtg, there was little to no difference in the 
progression and time to reach morbid status.  This is not surprising for the p53 and 
MDMXtg, since the over amplification MDMX prevents p53 from activating downstream 
targets, similar to the deletion of p53.  In addition, early reports of histological analyses 
found there to little difference in the tumor morphology [125].  Interestingly, with only one 
intact copy of p107, the p107s group tumors! phenotype was similar.  Even though p107 
is haploinsufficient it did impact tumor development [166].  This may suggest that the 
one copy still has some cell cycle control that affect the tumor progression and morbidity.  
The RB TKO group had similar tumor onset age to the other triple knockouts, but the 
time for the tumor to progress and morbid age was the earliest.   Therefore, the loss of 
all RB family members, thus complete loss of cell cycle control, lead to fast and 
aggressive tumors.  While this analyses are informative, they are not conclusive can be 
strengthened with genetic studies on the tumors and compared to human tumors. These 
would include microarray analyses, comparative genomic hybridization and SKY assay. 
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My graduate thesis work has addressed two specific issues relevant to the 
assessment and development of preclinical approaches for the treatment of 
retinoblastoma.  First, I conducted a preclinical study looking at the combination of a 
local and systemic administration of carboplatin and topotecan.  I found a local injection 
could increase the drug exposure in the vitreous and decrease systemic exposure.  This 
is an important finding for children with the germline mutation.  In addition, an ideal 
combination of two well-studied board spectrum chemotherapy agents, carboplatin in the 
subconjunctival space and topotecan i.p., has shown good tumor response with minimal 
systemic and local toxicity.  I have also optimized the use of clinical modalities for mice 
and determined tumor progression in various models.  Not only does this non-invasive 
longitudinal study make the preclinical research truly translational, but also gives a sense 
of retinoblastoma growth and progression in various mouse models of retinoblastoma.  
These finding will lay the foundation for future preclinical studies and help define the role 
of different genes in retinoblastoma tumor formation. 
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APPENDIX A.  DRUG TRANSPORTERS IN THE EYE 
 
 
Table A-1. An Abbreviated Summary of Drug Transporters in the Eye. 
 
Tissue Transporter Species Reference 
Blood-retina-
barrier 
 
P-gp (MDR) Porcine [92] 
 MRP1 
 
Porcine [92] [175] 
RPE  P-gp 
 
Human, rabbit [16, 176] 
 OCT3 Mouse, rabbit, 
human 
 
[177] 
 OATP-E 
 
Rat  [178] 
Lens P-gp 
 
Rat [179] 
Ciliary 
epithelium 
 
P-gp Bovine [180] 
Cornea P-gp 
 
Rabbit, human [181] 
 OATP-E 
 
Rat [178] 
Conjunctiva P-gp (apical 
/tear side) 
 
Rabbit, human [182, 183] 
 OCTs Rabbit, mouse, 
human 
[183, 184] 
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APPENDIX B.  PHARMACOKINETICS AND AUC GUIDED DOSING FOR 
CARBOPLATIN AND TOPOTECAN IN HUMANS AND RODENTS 
 
 
B.1 SYSTEMIC TOPOTECAN  
 
Preclinical studies have suggested that attaining a specific plasma topotecan 
lactone systemic exposure (i.e. AUC) was associated with an improved antitumor effect 
in pediatric solid tumor xenografts [167].  Thus, numerous clinical trials in children with 
cancer have used the approach of pharmacokinetically guided topotecan dosing to 
individualize topotecan therapy for a patient based upon that child!s topotecan systemic 
clearance.  This approach takes advantage of the linear relationship between topotecan 
dosage and plasma area under the concentration-time curve (AUC) to account for the 
wide interpatient variability noted in topotecan clearance [168] to achieve the target 
topotecan systemic exposure (AUC), which is defined differently for each clinical trial 
depending upon the therapeutic goal.  For example, in a study of children with high-risk 
medulloblastoma administered topotecan intravenously daily for 5 days, the target was 
defined as a plasma topotecan lacton AUC of 120 to 160 ng/ml"hr (~0.26-0.35 µM"h 
topotecan lacton or ~0.79-1.1 uM"h topotecan total [lactone and carboxylate]) [169].  In 
this study, the median topotecan dosage associated with the studies that were within the 
target range was 3.2 mg/m2/dose.  In current institutional study for children with 
retinoblastoma, the same topotecan lactone target systemic exposure (i.e. 120 to140 
ng/ml"hr) and dosing approach is used.  Our orthotopic xenograft studies are carried our 
in juvenile rats (P14) [60].  To directly convert the human dosage in mg/m2 to a juvenile 
rat dosage in mg/kg, we considered that although the size of our juvenile rats (~28-30 g) 
is similar to the size of an adult mouse, drug metabolism and clearance mechanisms (in 
particular, those depend on the liver and kidneys) may be significantly different in 
juvenile rats due to their incomplete development.  Therefore, in order to calculate 
human-equivalent dosages in juvenile rats, we did not use species-specific conversion 
factors (based purely on body surface area and weight), which have been developed for 
adult rat (factor 6) and adult mice (factor 3), but not for juvenile rats [170].  Instead, we 
preferred a dosing approach that was “AUC guided,” based first on determining a 
desired or appropriate systemic exposure or AUC in patients, and then with our 
knowledge of the pharmacokinetics of the drug in the animal model calculate what 
dosage would be required to attain that systemic exposure or value in animal model.   
 
Using this approach we would first chose the topotecan lactone systemic 
exposure or AUC value form the retinoblastoma clinical trial as our “target” for the animal 
model (i.e., 120 to 60 ng/ml"h).  Results of previous pharmacokinetic studies in this 
animal model juvenile (P14) rats reformed in our lab showed that after a 2 mg/kg i.p. 
injection of topotecan, the total topotecan AUC was 1230 ng/ml"hr (2.7 µM"h) [60].  This 
is approximately 2.7 to 3.4-fold higher than the above described topotecan AUC target 
for the clinical retinoblastoma protocol.  Since the relationship between topotecan 
dosage and AUC is linear, a dosage of 0.7 mg/kg in P14 rats is estimated to yield the 
equivalent of a plasma topotecan lactone AUC of 140 ng/ml"h.  Therefore, topotecan 
given at a dosage of 0.7 mg/kg i.p. daily x 5 is our candidate equivalent dosage based 
on pediatric plasma AUC measurements.  A similar study in adult mice found that the 
dose of 0.6 mg/kg on a daily x 5 (x2) schedule was well tolerated and gave a topotecan 
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lactone AUC of 88 ng/ml"hr [170].  It may be necessary to increase 1.6-fold the dosage 
in adult mice to achieve the equivalent of the desired topotecan lactone AUC of 140 
ng/ml"hr.  Based on this approach, the human equivalent i.p. topotecan dosage for P14 
rats is 0.7 mg/kg and 1 mg/kg for adult mice.   
 
 
B.2 SUBCONJUNCTIVAL TOPOTECAN  
 
In 2009, Chantada administered subconjunctival topotecan to children with 
retinoblastoma, and found that the maximum tolerated dose was 2 ml or 2 mg per eye 
[67].  A 30 lb child that is 25 inches tall and 30 months old (59th percentile from growth 
charts) has a body surface area (BSA) of 0.49 m2. Therefore, a dose a 2mg is equivalent 
to 4 mg/m2.  Based on previous topotecan AUC data for systemic administration, the 
plasma AUC should be 240-320 ng/ml"h if the drug is absorbed systemically in a 
manner similar to a 30 minute i.v. infusion.  This assumption is not necessarily true.  The 
total plasma AUC achieved from a 2 mg subconjunctival injection of topotecan was much 
lower at 104 ng/ml "h (G. Chantada, personal communication).  The volume of the 
subconjunctival space and the drug concentration provided by the manufacturer limits 
the total dose.   
 
The volume of an average child!s eye with retinoblastoma is ~3600 mm3.  
Therefore, if 2 mg is administered per eye, the maximum ocular concentration would be 
0.55 mg/ml of eye volume.  As an approach to calculate equivalent local topotecan 
dosages in P14 rats, we considered literature data on the volume of an adult mouse eye 
(19.1 mm3) [171].  For a mouse eye of 19.1 mm3 the dose would be ~0.01 mg per eye to 
achieve the same maximum exposure of 0.55 mg/ml of eye volume.  In our 
pharmacokinetic studies, we administered 0.01 ml of a 1 mg/ml stock.  This is equivalent 
to the human dose according to our rationale.  We performed a pharmacokinetic study of 
subconjunctival topotecan (0.01 mg/eye) in both eyes of P14 rats to directly compare to 
the data from Chantada [67].  We analyzed total topotecan concentration in plasma and 
found that the topotecan AUC total from this experiment was 524 ng/ml"h.  Thus, the 
plasma AUC from a single injection of topotecan to one eye was 104 ng/ml"h for 
humans as compared to 262 ng/ml"h per mouse eye.  We have not performed a 
pharmacokinetic study in adult mice using subconjunctival injection of topotecan to 
determine if the systemic or vitreal exposure is different between adult mice and juvenile 
rats.  It is also important to consider the possibility that there may be an increase in the 
side effects of subconjunctival topotecan in juvenile rats as compared to humans 
because of this increase in systemic exposure.  Since no data are available from vitreal 
topotecan AUC values in humans, we could not compare our murine data and derive 
dosing recommendations as with systemic topotecan therapy.  However, we believe that 
our selection of a topotecan dose of 0.01 mg/eye for our rodent studies is rational based 
upon the proposed eye volume approach. 
 
 
B.3 TOPOTECAN SUMMARY  
 
Based on these data, the human equivalent i.p. topotecan dosage for P14 rats is 
0.7 mg/kg and 1 mg/kg for adult mice.  The human equivalent dose for subconjunctival 
injection of topotecan in rodents is 0.01 mg/eye.  
 89 
 
B.4 SYSTEMIC CARBOPLATIN  
 
The dosage of intravenous carboplatin used in children with cancer including 
those with retinoblastoma is 550-560 mg/m2 [123, 172].  The plasma AUC for the dose 
can range from 260-430 µM"hr [123, 172].  A linear relationship has been noted 
between AUC and carboplatin dosages.  However, as with many anticancer drugs in 
children, wide interpatient variability in carboplatin systemic clearance has been reported 
[173].   
 
The equivalent carboplatin dosage, using the conversion factors based on body 
surface area and weight, for the adult rat is ~90 mg/kg and ~180 mg/kg in adult mice 
[170].  As with topotecan, it is likely that the disposition of the carboplatin varies among 
species.  The LD10 for adult mice was 165 mg/kg [174].  Therefore, it is impossible to 
administer the converted dose (180mg/kg) based on body weight in adult mice.  
  
Previous studies using juvenile (P14) rats and a 70 mg/kg i.p. dose (equivalent to 
210-420 mg/m2 in children) gave a plasma AUC of 560 µM"h [60].  This is approximately 
2-fold higher than the target AUC for children.  Considering that the dose-to-AUC 
relationship is linear, a dose of 35 mg/kg should give a plasma AUC in P14 rats of ~280 
µM"h.  A similar study performed in adult mice found that the dose of 165 mg/kg resulted 
in a plasma AUC of 487 µM"h.  Therefore, in adult mice found that the dose of 165 
mg/kg resulted in a plasma AUC of 487 µM"h.  Therefore, in adult mice, it may be 
necessary to increase the i.p. to ~80 mg/kg to achieve exposure similar to those seen in 
humans [172].  
 
 
B.5 SUBCONJUNCTIVAL CARBOPLATIN  
 
Abramson performed a human Phase I/II clinical trial of subconjunctival 
carboplatin with a maximum dose of 20 mg/eye [65].  Using the conversion described 
above based on the volume of the rodent eye compared to the human eye, a dose of 0.1 
mg/eye is equivalent to the human dose.  Our AUC analysis of P14 rats using bilateral 
injection of 0.1 mg/eye resulted in a plasma AUC of 63 µM"h.  No plasma AUC data are 
available for the 20 mg subconjunctival injection in humans. 
 
 
B.6 CARBOPLATIN SUMMARY  
 
Based on these data, the human equivalent i.p. carboplatin dose for P14 rats is 
34 mg/kg and 80 mg/kg for adult mice.  The human equivalent dose for subconjunctival 
injection of topotecan in rodents is 0.2 mg/eye.  
 90 
VITA 
 
 
Katie Marie Nemeth was born in Hartford, Wisconsin in 1976.  She graduated 
from West Bend West High School in June of 1994.  In 1999, she completed her double 
major in French and Biology from Marquette University.  She enrolled in the 
Interdisciplinary Program of Biomedical Sciences at the University of Tennessee in 2004.  
Her dissertation research was conducted at St. Jude!s Children!s Research Hospital.  
She completed her doctorate work May 2010. 
